TITLE P AGE  
 
 
  
 
A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop  
 
PROTOCOL 
STUDY # 952 
Sponsor: 
Bausch & Lomb Incorporated  
 
This clinical investigation is being conducted in accordance with 21 Code of Federal Regulations (CFR) 
Parts 11, 50, 54, 56, and 812. The protocol was developed with consideration of the provisions in: 
International Organization for Standardization (ISO) 1 4155- 1:2011 Clinical investigation of medical 
devices for human subjects – Part 1:  General requirements; [ZIP_CODE] -2:2011 Part 2:  Clinical investigation of 
medical devices for human subjects – Part 2:  Clinical investigational plan; ISO [ZIP_CODE]:2012 Ophthalmic  
Optics – Contact [CONTACT_224068] – Guidance for clinical investigations; International 
Conference on Harmonisation (ICH) Good Clinical Practice (GCP)  – Declaration of Helsinki and  
applicable local regulations. The Sponsor intends to register this clinical trial with the public database 
https://ClinicalTrials.gov.  
 
Revision Chronology:  
Amendment [ADDRESS_291947] udy personnel, and the applicable IRB/EC. By [CONTACT_11217], you 
agree that the information contained herein will not be disclosed to others without written authorization 
from Bausch & Lomb Incorporated, except to the extent necessary to obtain consent from those persons 
who particip ate in this study.  
 
Ultra®, Pure Vision®2, Sensitive Eyes®, Simplus® and Biotrue® are registered trademarks of Bausch 
+ Lomb, Incorporated. All other brand names/product names are trademarks of their respective 
owners.  
 
 
 
 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 3 of 72 
 INVESTIGATOR STATEMENT OF APPROVAL  
 
A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop  
PROTOCOL 
STUDY #[ADDRESS_291948] this study in accordance with 21CFR Parts 11, 50, 54, 56, 812, and 
42 USC 282(j); and with consideration of the provision in: ISO [ZIP_CODE]-1:2011 Clinical 
investigation of medical devices for human subjects – Part 1: General requirements; 
[ZIP_CODE]-2:2011  Part 2: Clinical investigation of medical devices for human subjects – Part 
2: Clinical investigational plan; ISO [ZIP_CODE]:2012 Ophthalmic Optics – Contact [CONTACT_240349] – Guidance for clinical investigations; ICH, GCPs,  
Declaration  of Helsinki and applicable local regulations. I will not initiate the study until 
I have obtained written approval by [CONTACT_240350]. I will obtain written informed consent from each study subject prior to performing any study specific procedures.  
I understand that my signature [CONTACT_240419]/Protocol and to review and, if appropriate, sign the clinical study report.  
I understand that my e -signature [CONTACT_240420] [INVESTIGATOR_048].  
I understand that this document and related information is subject to confidentiality terms found in my signed Confidentiality or Clinical Services Agreement. I agree to protect the confidentiality of my patients when allowing the Sponsor of this clinical investigation, and/or relevant regulatory authorities and IRBs, direct access to my medical records for study subjects. 
 
  
Principal Investigator, Printed Name  
 
    
[INVESTIGATOR_678], Signature  [CONTACT_240421], provide a copy of this page to Bausch & Lomb Incorporated and retain a copy for 
your files.  
 
 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 4 of 72 
 SYNOPSIS  
Name [CONTACT_790]/Company:   Bausch & Lomb  Incorporated  
Name [CONTACT_791]:   BL-300-PFM04  Preservative Free Lubricating and Rewetting Drops  
Name [CONTACT_3261]:   Sodium  Hyaluronate and Glycerol  
Title of Study:  A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop  
Primary Objective :  The objective of this study is to evaluate the safety and effectiveness of lubricating 
and rewetting drop (Test) compared to OPTI -FREE ® Replenish ® Rewetting Drops (Control) when used 
by [CONTACT_240351] (hydrophilic) contact [CONTACT_240352] (silicone  acrylate and fluoro  silicone 
acrylate) contact [CONTACT_13276] .  
Secondary: None  
Methodology:  This is a multicenter, randomized, masked, parallel, bilateral clinic al trial.   
Number of patients planned:  Approximately 368 subjects  (736 eyes; 184 subjects  per treatment arm)  
will be enrolled.  
Diagnosis and main criteria for inclusion:  
• Subjects must be of legal age (at least 18) on the date the Informed Consent Form (ICF) is signed 
and have the capacity to provide voluntary informed consent  
• Subjects must be habitual wearers of included contact [CONTACT_13276].   
• Subjects must be adapted lens wearers and wear a lens in each eye and each lens must be of the 
same manufacture and brand.   
• Subjects must agree to wear their lenses on a daily wear basis for approximately 1 month.  
Key exclusion criteria:   
• Subjects partic ipating in any drug or device clinical investigation within two weeks prior to entry 
into this study and/or during the period of study participation.  
Investigational product, dosage and mode of administration:  BL-300-PFM04 Preservative Free 
Lubricating  and Rewetting Drops for use during contact [CONTACT_13279] . 
Duration of treatment: 1 month  
Reference therapy, dosage and mode of administration: OPTI -FREE Replenish Rewetting Drops  
Criteria for evaluation:    
The primary endpoints are as follows.  
Effectiveness :   
1. Overall comfort averaged over all follow -up visits  
2. Dryness averaged over all follow -up visits  
Safety: 
1. Slit lamp findings greater than grade 2 at any follow- up visit 
Statistical methods:    
Continuous variables will be summarized using the sample size, mean, standard deviation, median, minimum, and maximum. Categorical variables will be summarized using frequencies and percentages.  
Each primary endpoint will be evaluated statistically using a one -sided non- inferiority test with a one -
sided alpha risk of 0.05. For overall comfort and dryness, each non -inferiority hypothesis will be tested 
using an analysis  of variance model including the fixed factor of treatment and the fixed blocking factor 
of site  with a non -inferiority margin magnitude of five points. For slit lamp findings, the non-inferiority 
hypothesis will be tested using a one-sided Newcombe -Wilson  95% upper confidence limit with a non -
inferiority margin magnitude of 5%. 
Sample size calculations:  
In a previous study (Bausch + Lomb study 872), the following outcomes were observed. These outcomes 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 5 of 72 
 serve as expected results for the current study.  
1. Overall comfort averaged over all follow -up visits: standard deviation = 13.9 points  
2. Dryness averaged over all follow -up visits: standard deviation = 13.9 points  
3. Slit lamp findings greater than grade 2 at any follow- up visit were observed in 0.5% of eyes  
When the sample size is 160 subjects per treatment group, the overall power of the trial will be 97%. To 
allow for losses of up to 13 %, approximately [ADDRESS_291949] ARTICLE (S)/TREATMENT (S) .........................................................................  18 
4.2 DESCRIPTION OF COMPARATOR [PRODUCT (S)/TREATMEN T(S)] .......................................................  [ADDRESS_291950] INSTRUCTIONS  ...................................................................................................................  19 
4.4 PACKAGING AND LABELING  ............................................................................................................  19 
4.4.1  LENSES  ............................................................................................................................................  19 
4.4.2  STUDY KITS .....................................................................................................................................  19 
4.4.3  OTHER STUDY SUPPLIES  ..................................................................................................................  19 
4.5 RETURN OF STUDY MATERIALS  .......................................................................................................  20 
4.6 ACCOUNTABILITY  ............................................................................................................................  20 
4.7 MASKING /UNMASKING  ....................................................................................................................  [ADDRESS_291951] REPLACEMENT  .................................................................................................................  22 
4.9 RISK ASSESSMENT  ...........................................................................................................................  22 
5.0 SAFETY AND EFFECTIVE NESS VARIABLES  ..........................................................................  22 
5.1 SAFETY VARIABLES  .........................................................................................................................  22 
5.2 PRIMARY EFFECTIVENESS VARIABLES  ............................................................................................  22 
5.3 RISK ASSESSMENT  ...........................................................................................................................  22 
6.0 STUDY METHODS ...........................................................................................................................  22 
6.1 STUDY VISITS  ..................................................................................................................................  22 
6.1.1  SCREENING /DISPENSING VISIT ........................................................................................................  23 
6.1.2  2-W EEK FOLLOW -UP VISIT ..............................................................................................................  25 
6.1.3  1-M ONTH FOLLOW -UP .....................................................................................................................  26 
6.1.4  EXIT VISIT .......................................................................................................................................  28 
6.1.6  MISSED VISITS  ................................................................................................................................. 30 
6.2 STUDY COMPLETION  ........................................................................................................................  31 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 8 of 72 6.2.1  EARLY STUDY TERMINATION /SUSPENSION  .....................................................................................  31 
6.3 CONCOMITANT MEDICATIONS /THERAPY  .........................................................................................  31 
6.4 TREATMENT COMPLIANCE  ...............................................................................................................  31 
6.5 PROTOCOL DEVIATIONS  ...................................................................................................................  31 
7.0 ADVERSE EVENTS  .........................................................................................................................  32 
7.1 ADVERSE EVENT DEFINITIONS  ........................................................................................................  32 
7.1.1  ADVERSE EVENT (AE)  .....................................................................................................................  [ADDRESS_291952] (ADE)  ....................................................................................................  [ADDRESS_291953] (ASADE)  ................................................  [ADDRESS_291954] (UADE)  .............................................  33 
7.1.3  SERIOUS ADVERSE EVENT (SAE)  ....................................................................................................  33 
7.1.4  SIGNIFICANT NON-SERIOUS ADVERSE EVENTS  ...............................................................................  34 
7.1.5  NON-SIGNIFICANT NON-SERIOUS ADVERSE EVENTS  .......................................................................  34 
7.2 ADVERSE EVENT TREATMENT AND CULTURING  ..............................................................................  35 
7.3 EVALUATIONS  ................................................................................................................................. 35 
7.3.1  SEVERITY  .........................................................................................................................................  35 
7.3.2  RELATIONSHIP TO STUDY DEVICE AND /OR REWETTING DROPS  .......................................................  [ADDRESS_291955] REPORTING  ...................................  37 
7.4.2  REPORTING DEVICE DEFICIENCIES  ..................................................................................................  37 
7.4.3  GUIDELINES FOR REPORTING PREGNANCIES  ....................................................................................  37 
8.0 STATISTICAL METHODS  .............................................................................................................  38 
8.1 STUDY ENDPOINTS  ..........................................................................................................................  38 
8.1.1  Primary Safety Endpoint .......................................................................................................  38 
8.1.2  Primary Effectiveness Endpoints  ..........................................................................................  38 
8.1.3  Secondary Effectiveness Endpoints  ......................................................................................  38 
8.2 HYPOTHESES ....................................................................................................................................  38 
8.2.1  Slit Lamp Findings  ...............................................................................................................  38 
8.2.2  Overall Comfort  ....................................................................................................................  39 
8.2.3  Dryness  ................................................................................................................................. 39 
8.3 SAMPLE SIZE ...................................................................................................................................  39 
8.3.1  Slit Lamp Findings  ...............................................................................................................  39 
8.3.2  Overall Comfort  ....................................................................................................................  39 
8.3.3  Dryness  ................................................................................................................................. 40 
8.3.4  Overall Power  .......................................................................................................................  40 
8.3.5  Enrollment Target  .................................................................................................................  40 
8.4 RANDOMIZATION  .............................................................................................................................  40 
8.5 STUDY POPULATIONS  ......................................................................................................................  40 
8.5.1  Intent -to-Treat (ITT) Population  ...........................................................................................  40 
8.5.2  Per Protocol (PP) Population  ................................................................................................ [ADDRESS_291956] /ETHICS COMMITTEE APPROVAL  ...................................................  [ADDRESS_291957] of the Investigation  ....................................................................................  46 
9.8.3  Informed Consent Process  ....................................................................................................  46 
10.0 REFERENCES  ...................................................................................................................................  48 
 
  
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 10 of 72 APPENDICES  
APPENDIX A:  SCHEDULE OF VISITS A ND PARAMETERS  ..................................................  A-1 
APPENDIX B:  METHODS OF CLINICAL EVALUATION  ........................................................B-1  
APPENDIX C:  CORNEAL INFILTRATES EVALUATION FORM  .......................................... C-1  
APPENDIX D:  CULTURE PROCEDURE  .....................................................................................  D-1 
APPENDIX E:  SUBJECT INSTRUCTIONS  – SOFT CONTACT [CONTACT_240353] ............................... E-1 
APPENDIX F:  SUBJECT INSTRUCTIONS  – RIGID CONTACT [CONTACT_126127]  .............................  F-[ADDRESS_291958]  
IB  Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
ID identification  
IDE Investigational Device Exemption  
IRB Institutional Review Board  
ISO International Organization for Standardization  
ITT intent -to-treat 
logMAR  logarithm of the minimum angle of resolution  
MCMC  Markov chain Monte Carlo  
OD Doctor of Optometry  
ORS  Oracle Randomization and Supplies Management  
PP per-protocol  
PAL  Product Accountability Log  
QID [ADDRESS_291959]  
US [LOCATION_002]  
[LOCATION_003]N  [LOCATION_002] Adapted Name  
[CONTACT_240422]:  The first occurrence of some abbreviations is not spelled out in the  document ( eg, units of 
measure).  
 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 12 of 72 1.0 INTRODUCTION  
Bausch + Lomb is evaluating the investigational BL -300- PFM04 Preservative Free 
Lubricating and Rewetting Drops for use with soft (hydrophilic) contact [CONTACT_240354] (silicone acrylate and fluoro silicon e 
acrylate) contact [CONTACT_13276].  
The aim of this study is to evaluate the clinical performance of the investigational  
lubricating and rewetting drops when compared to currently marketed OPTI -FREE® 
Replenish® Rewetting Drops. All subjects will care for their le nses with specified 
cleaning and disinfecting solutions, and lens cases. 
2.0 OBJECTIVE 
The objective of this study is to evaluate the safety and effectiveness of BL -300- PFM04 
Preservative Free L ubricating and Rewetting Drops (Test) compared to OPTI -FREE  
Replenish R ewetting Drops (Control) when used by [CONTACT_240355] (hydrophilic) contact [CONTACT_240356] (silicone acrylate and fl uoro silicone acrylate) lenses .  
3.0 STUDY D ESIGN  
This is a multicenter, randomized, masked, parallel, bilateral clinical trial.  3.1 Description of Study Design   
Approximately 368 subjects ( 736 eyes) will be enrolled in this multicenter, randomized, 
masked, parallel, bilateral study at approximately 12-16 investigative sites in the United 
States (US). Approximately one -half of the eligible subjects will be randomized to 
receive Bausch + Lomb investigational BL -300- PFM04 Preservative Free Lubricating 
and Rewetting Drops , and approximately one -half of the subjects will be randomized to 
receive OPTI -FREE Replenish
 Rewetting Drops. In addition, all subjects will be 
dispensed two new pairs ( 1 to wear, 1 back-up) of their habitual lenses at the beginning 
of the study for daily wear.  A third pair will be kept at the site for each subject.  
All subjects will be seen for a Screening/Dispensing Visit, at which informed consent 
will be obtained and e ligibility will be assessed. If eligible, subjects will be dispensed two 
new pairs of their habitual contact [CONTACT_240357] a Study Kit containing a supply of either the test or control r ewetting drops , according to the subject’s randomly assigned treatment .  
The subject will also be dispensed lens care products ( Biotrue multi- purpose solution or 
[LOCATION_011] SIMPLUS
® Multi- Action Solution and lens cases) sufficient for the entire study.  
Subjects must NOT use ANY other cleaning and disinfecting solution or rewetting  drops 
during the study.   
Subjects will be required  to wear their study lenses for a minimum of [ADDRESS_291960] 4 times per day . Subjects are to use the specified lens care products after removing 
the lenses each day.  Subjects will return their full, partially full and empty rewetting  
drop bottles/single -use dispensers and  worn  and unworn  lenses to the unmasked designee 
at the 1- month follow up /exit visit (or early discontinuation visit) for return to the 
Sponsor.  It is not necessary to return any bottles of  Biotrue multi- purpose solution or 
[LOCATION_011] SIMPL US Multi-Action Solution or unused lens cases. 
Study [ADDRESS_291961] lenses. Subjects will be randomized on a 1:[ADDRESS_291962] lenses 
based on lens material as indicated in table  below.   
Table 1: Lens Groups  
Lens Group  Lens Material  Trade 
 Manufacturer  
4 Etafilcon A  Acuvue2  Vistakon  
5-A Balafilcon A  PureVision2  Bausch + Lomb  
5-B Efrofilcon A, Fanfilcon A, Somofilcon A  N/A N/A 
5-C Samfilcon A  Ultra  Bausch + Lomb  
5-Cm Lotrafilcon B  Optix Aqua  Alcon  
5-Cr Senofilcon C Vita Vistakon  
Gas Permeable  SA, 
Group II   To include, but not limited:  Dimefocon A, 
Itafocon A and B, Synergicon A , Kolfocon A and 
B, Pasifocon A  and C 
 N/A N/A 
Gas Permeable  FSA, 
Group III   To include, but not limited:  Paflufocon A, B,C and 
D,  Unifocon A, Oxyflufocon A , Enflufocon A and 
B, Flusilfocon A,  B and C, Hexafocon A and B, 
Hofocon A, Hybufocon A, Itafluorofocon A, Lotifocon B and C, Onsifocon A, Oprifocon A, Pemufocon A, Roflufocon A, C, D and E, 
Wilofocon A  N/A N/A 
3.[ADDRESS_291963] (IRB) approval to conduct the study. The Sponsor and IRB must approve any advertising used to recruit subjects prior to use of that advertising.  
All consented subjects must be accounted for, whether they participate in the study or not. Bausch + Lomb will provide a Screening Log on which to enter information for each subject who signs an Informed Consent Form (ICF). All screened subjects must b e 
entered onto the Screening Log, to include the subject identification (ID) number assigned by [CONTACT_240358] . Once a potential subject is consented and their 
initials are entered onto the Screening Log, the Investigator should proceed with Screening procedures. 
Potential subjects are deemed either “Screen Pass” or “Screen Fail.” “Screen Fail” subjects are subjects who have not met the study eligibility  criteria and cannot be 
randomized into the study. Each subject will be assigned a subject iden tification (ID) 
number by [CONTACT_240359] a “Screen Pass” or 
“Screen Fail”. 
Only “Screen Pass” subjects can be randomized by [CONTACT_240360].  
Once a subject is randomized, a subject is considered active and must be accounted for at 
every visit until exited (completed or discontinued) from the study, even if they are not dispensed study materials. Refer to  Section  3.2.[ADDRESS_291964] meets all of the 
following criteria:  
1. Is of legal age (at least 18) on the date the Informed Consent Form (ICF) is signed and has the capacity to provide voluntary informed consent.  
2. Is able to read, understand, and provide written informed consent on the Institutional Review Board (IRB) appro ved ICF and provide authorization 
as appropriate for local privacy regulations. 
3. Is a habitual wearer (at least 3 months) of one of the lens types included in 
Table 1: Lens Groups  (page 13) . 
4. Is correctable through spherocylindrical refraction  to 32 letters 
(0.3 logMAR) or better (distance, high contrast) in each eye.  
5. Has clear central corneas and is free of any anterior segment disorders.  
6. Is a habitual user of a lens care product for cleaning, disinfecting, and storage of lenses.  
7. Wears a lens in each eye and each lens must be of the same manufacture 
and brand. 
8. Wears their habitual lenses (or be willing to wear lenses) a minimum of [ADDRESS_291965] 4 times 
per day when lenses are worn. 
10. Is willing and able to comply with all treatment and follow -up/study 
procedures. 
 Exclusion Criteria  
The subject is inelig ible for entry into the study if the subject meets any of the 
following criteria:  
1. Subjects who currently use a hydrogen- peroxide cleaning and disinfecting 
solution. 
2. Participating in any drug or device clinical investigation within 30 days prior to entry into this study and/or planning to do so during the period of study participation. 
3. Females of childbearing potential (those who are not surgically sterilized or postmenopausal) if they meet any one of the following conditions: 
‒ they are currently pregnant 
‒ they plan to become pregnant during the study 
‒ they are breastfeeding  
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 15 of 72 4. Current user of the control rewetting drops (OPTI -FREE Replenish 
Rewetting Drops). 
5. Has worn polymet hylmethacrylate (PMMA) lenses within the last  
three months.  
6. Has any systemic disease currently affecting ocular health or which in the 
Investigator’s opi[INVESTIGATOR_240340]. 
7. Has any ocular disease or is using any ocular medication.  
8. Is using any systemic or topi[INVESTIGATOR_240341], in the Investigator’s opi[INVESTIGATOR_1649], affect ocular physiology or lens performance. 
9. Currently wears monovision, multifocal, or toric contact [CONTACT_13276]. 
10. Subjects who are adapted soft lens wearers with ocular astigmatism of 1.00D or greater in either eye. 
11. Has anisometropia (spherical equivalent) of greater than 2.00D.  
12. Has any grade 2 or greater finding during the slit lamp examination (refer to 
APPENDIX B:  Methods of Clinical Evaluation ). Subjects with corneal 
infiltrates, of ANY GRADE, are not eligible.  
13. Subjects with any “Present” finding during the slit  lamp examination (refer 
to APPENDIX B:  Methods of Clinical Evaluation ) that, in the Investigator’s 
judgment, interferes with contact [CONTACT_13279].  
14. Has any scar or neovascularization within the central 6 mm of the cornea. Note that subj ects with minor peripheral corneal scarring (that does not 
extend into the central area), that, in the Investigator’s judgment, does not interfere with contact [CONTACT_13279], are eligible for this study.  
15. Is aphakic.  
16. Is amblyopic. 
17. Has had any corneal surgery ( e.g., refractive surgery).  
18. Is allergic to any component in the study care products. 
19. Subjects who meet any of the following criteria: 
‒ the subject is an employee of the investigative site  
‒ the subject, or a member of the subject ’s household, is an 
Ophthalmol ogist, an Optometrist, an Optician, or an Ophthalmic 
Assistant/Technician  
‒ the subject, or a member of the subject ’s household, is an employee of 
a manufacturer of contact [CONTACT_240361] ( e.g., 
Alcon, Bausch + Lomb, Ciba Vision, Cooper Vision, Johnson & 
Johnson, etc.) 
20. Subjects who are adapted GP wearers with an ocular astigmatism of 3.00D or greater in either eye.  
If a subject meets all the inclusion criteria and does not exhibit any of the exclusion criteria, the subject is eligible for entry into the study. Ineligible subjects MUST NOT be 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 16 of 72 enrolled in this study and are considered a “Screen Fail”. Any subject enrolled in the 
study who later is found to have not met the eligibility criteria at entry will be discontinued. 
3.2.[ADDRESS_291966] MAY be discontinued (at the discretion of the Investigator, the Sponsor, and/or 
the IRB) prior to the final study visit for a variety of reasons, including, but not limited to:  
• An adverse event (AE) occurring during the course of the study, which precludes continued treatment or follow-up 
• Persistent Grade 3 or 4 slit lamp findings (must be reported to the Sponsor within  24 hours) 
• Persistent study -related symptoms/complaints  
A subject MUST be discontinued prior to the final study visit ( 1-Month V isit [Visit 3]) 
for any of the following reasons: 
• V oluntary withdrawal 
• Death  
• Investigator decision that it is not in the best medical interest of the subject to 
continue participation in the investigation  
• Ineligible at screening/dispensing  – a subject who was enrolled but was later 
found to have not met the eligibility criteria  
• Inability to maintain recommended wearing  and rewetting drop schedule 
• Continued failure to follow subject instructions 
• Lack of motivation 
• Lost t o follow-up (refer to 
Section 3.2.4) 
• Instillation of non-medically indicated solution not specified in the protocol 
• Other eye is discontinued  
• Becomes p regnant during the study 
Prior to discontinuing a subject, every effort should be made to contact [CONTACT_423], 
schedule an Exit Visit, obtain as much follow -up data as possible, and retrieve all study 
materials. Adverse events will be followed as described  in Section 7.0. Subject 
discontinuations will be documented clearly on the source document and applicable electronic case report form ( eCRF ). The Investigator should indicate the PRIMARY 
(one) reason that the  subject was discontinued for each eye. Subjects who are 
discontinued from the study following randomization will not be replaced. 
Exit Visit assessments should be completed for discontinued subjects.  
Study [ADDRESS_291967] 4 times per  day.   
4.0 STUDY MATERIALS  
Bausch + Lomb will provide all study solutions at no charge to the Investigator.  All 
study lenses are to be purchased through the site’s normal ordering process and will be reimbursed by [CONTACT_1034].  All other materials will be provided to the site prior to the start of the study.  Refer to Product Replacement Section 4.[ADDRESS_291968] lenses, not listed in Table 1: Lens Groups , or lens care products is 
not allowed. 
4.[ADDRESS_291969] Article(s)/Treatment(s)   
PFM04 is a preservative -free, sterile isotonic aqueous solution containing glycerol (0.5%) 
and sodium hyaluronate (0.15%) drop manufactured by [CONTACT_59268] & Lomb Incorporated, 
[COMPANY_002]ster, NY  for lubricating and rewetting soft (hydrophilic) contact [CONTACT_240362].
 
4.2  Description o f Comparator [Product(s)/Treatment(s)]  
OPTI -FREE  Replenish  Rewetting Drop is a sterile, buffered, isotonic, aqueous solution 
that contains a citrate/borate buffer and sodium chloride with edetate disodium 0.05% 
and POLYQUAD (polyquaternium -1) 0.001% as pr eservatives and RLM- 100 (PEG -11 
lauryl ether carboxylic acid) and TETRONIC®1 1304 manufactured by [CONTACT_240363], Inc., Fort Worth, TX  for rewetting  soft (hydrophilic) contact [CONTACT_13276] ,  
fluorosilicone acrylate  and  silicone acrylate gas permeable contact [CONTACT_13276], and silicone 
hydrogel contact [CONTACT_13276]. 
4.[ADDRESS_291970] will be issued a Study Kit labeled with a unique 
Study Kit number. Subjects will be dispensed two pairs (one for back- up) of their 
habitual lenses at the Screening/Dispensing Visit . Subjects will be required to wear their 
study lenses for a minimum of [ADDRESS_291971] Instructions provided at the Screen ing/Dispensing visit.   
In order to ensure that the Investigator and site staff remain masked to the study rewetting 
drops, an unmasked designee at the site will be responsible for all dispensation and collection of study supplies for  the subjects.  
Subjects are to be instructed not to discuss or show the dispensed study drops  to the 
Investigator or site staff during the study.  
Study [ADDRESS_291972] Instructions along with each Study Kit  of study 
solution for the use with the  study articles (refer to  Subject instructions  APPENDIX 
F: for Subject Instructions). Subjects must comply with the instructions provided to 
them.  
b. The unmasked designee must review, with the subject, the Subject Instructions and the precautions and warnings for lens wear, lens care, handling, cleaning, and disinfecting, and return of study materials.   
c. Any subject who does not follow instructions to a degree that, in the Sponsor or Investigator's opi[INVESTIGATOR_1649], jeopardizes the subject's well -being or the validity of the study, 
will be discontinued.  
4.[ADDRESS_291973]’s habitual contact 
[CONTACT_240364]; two pairs will be dispensed to the subject at the 
Screening/Dispensing Visit ( one to wear and one  for back -up).  The third pair will be 
retained in -office in the event that a non- scheduled replacement is required.  Addi tional 
lenses should be ordered if the third pair is dispensed.  
4.4.[ADDRESS_291974] by [CONTACT_145913].  
Each  Study Kit will include the following materials:  
• Either 56 pouches  containing  5 single -use dispensers of BL-300- PFM04 
Preservative Free Lubricating and Rewetting Drops (Test) or six  bottles  of 
OPTI -FREE Replenish  Rewetting Drops  (Control).  The drops will be enclosed in 
a white carton.  Each carton, bottle or pouch will be labeled with an investigational 
label including the Study Kit number (a unique 5- digit number). One randomized 
Study Kit  will be provided to subjects at the Screening/Dispe nsing Visit . The subject 
number may be written on the outside carton ONLY.  The rewetting drops  should not 
be written on or labelled.   
4.4.3 Other Study Supplies  
The following will be stored at the sites to be provided to subjects: 
• One 10 FL. OZ.  bottle of Baus ch + Lomb Biotrue  multi- purpose solution .  
-or- 
• Three 3.5 FL OZ bottle s of [LOCATION_011] SIMPLUS M ulti-Action  Solution . 
• Lens case.   Subjects are required to use the supplied lens case s.  In the event  of 
replacement lenses, use a lens case to store the lens(es).  
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 20 of 72 • Zippered Bag.   To hold empty multi-dose rewetting drop bottles or opened single-
use dispensers.  
• Subject Instructions.  Will be provided at Screening/Dispensing visit.  
4.[ADDRESS_291975] ID sealable bag for return of all materials.  
• Study Kit  Return Materials.  The unmasked designee will place all  the subject’s 
Test or Control articles (Study Kit with unopened multi -use bottles or single -use 
dispensers,  partially full, and empty multi- use bottle s or single -use dispensers) into  an 
opaque S ubject ID sealable bag  along with worn/unworn lenses as described below . 
Do not seal the bag until full accountability at the study close out visit with the 
monitor is c omplete.  It is not necessary to return the Biotrue multi-purpose solution or 
[LOCATION_011] SIMPLUS Multi -Action Solution bottles or unused lens cases. 
 
• Lens Return Materials . The u nmasked designee will place worn lenses in a lens 
case filled with Bausch + Lomb Sensitive Eyes Saline Solution. Complete a worn 
lens l abel provided for each lens case returned  with identify ing information such as 
study number, site identification number, subject number, subject initials, lens type, 
date dispensed, date removed, quantity of lenses returned ( which should be one lens 
for each eye)  and adhere the label to zippered bag. If replacement lenses were used, 
use a separate lens case and zippered bag with identifying information. Place the 
zippe red bag(s)  containing the lens case(s)  into the opaque S ubject ID sealable bag 
with any unworn lenses and all Study Kits  as described above. Do not seal the bag 
until full accountability at the study close out visit with the monitor is complete.  
 
Use the s upplied pre-printed FedEx labels for return of the study materials to the 
Sponsor after close out visit.  
4.[ADDRESS_291976] Accountability Log (PAL) will be provided to the 
sites for rewetting drops and a  Lens Accountability Log (LAL) will be provided for 
lenses. 
The Unmasked Designee will instruct the subject to bring their Study K it (i.e., white  
carton  original ly containing 56 pouches of 5 single- use dispensers or 6 multi- use bottles) 
to the 1- Month visit  and will collect all study materials ( Study Kit  and lenses dispensed 
or provided to the subject) only at the final /exit study visit. Study materials  will not be 
collected at any other visit than the final/exit visit.  
At time points throughout the study and/or upon completion of the study, the 
Sponsor/Sponsor's representative will review and verify the Investigator's accountability records. Following verification, and as directed by [CONTACT_1034], all Study Kits  (Test and 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 21 of 72 Control) and lenses (worn and unworn) must be returned to the Sponsor at the address 
below using the study supplied pre-printed FedEx labels.  
Bausch & Lomb Incorporated 
Clinical Trial Materials Supply Chain, Area [ADDRESS_291977] [COMPANY_002]ster, [LOCATION_001] [ZIP_CODE] 
4.7  Masking/Unmasking  
This study is masked , therefore, the Investigator/site staff, subjects, and Bausch + Lomb 
personnel or designee(s) involved in the collection of study data will be masked to the 
study rewetting drops. Each site must have an unmasked designee that will be responsible 
for dispensing and accountability. This designee shall not participate in study assessments that may cause bias to the study data.  Study Monitors should ensure that the unmasked 
designee is documenting accountability throughout the study, and should perform only accountability  tasks  during study that ensures they remain masked. (e.g.  verify kit #, logs 
are present and being completed) .  Full accountability should be performed at study end. 
The randomization schedule will be created by [CONTACT_240365].  Personnel involved with repackaging of clinical trial material will also be unma sked.  Unmasked designees at the site will manage the dispensation and 
return of study rewetting drops and related supplies. All other study personnel will remain masked until database lock. Another research staff member may manage the dispensation of the habitual lenses.  
Study rewetting drops will be provided in sealed opaque cartons with Study K it numbers 
pre-printed on them. Although the Test and Control bottles /single- use dispenser s will be 
visibly different, attempts will be made to mask the subjects b y providing identical 
investigational labels and packaging identical kit cartons . Subjects will be instructed to 
place the drops  in the eye and blink out of the sight of the Investigator or site staff. 
Subjects are not to show the study bottles /single- use dispensers to the Investigator or site 
staff unless instructed to do so.  
If unmasking of a subject’s randomly assigned treatment is required, the Investigator (or 
other designee) is required to attempt to contact [CONTACT_240366].  If this attempt is successful, then t he Medical Monitor will 
contact [CONTACT_12064] (see Personnel and Facilities, Page 3) and obtain approval 
to grant permission to unmask.  Upon receipt of authorization from the Sponsor designee, the Medical Monitor will advise the Investigator (or another qualified designee) to log into the randomization system and unmask the subject.  If the Medical Monitor cannot be contact[INVESTIGATOR_530], the Investigator (or other qualified designee) should attempt to contact [CONTACT_3433] e 
Sponsor designee who can authorize the unmasking of a subject.  If the Medical Monitor or Sponsor designee cannot be contact[CONTACT_240367] (or other qualified designee) deems the unmasking to be an emergency , the Investigator may log into ORS 
without authorization and unmask the subject. Whether unmasking occurs inadvertently 
or intentionally, the Investigator must notify the Medical Monitor or Sponsor designee as soon as possible after unmasking. In addition, the Investigator must record the dat e, time, 
and reason for unmasking the study treatment in the source documentation. 
Study [ADDRESS_291978] Replacement  
Any additional/replacement (in the case of loss or damage) Test or Control rewetting 
drops must be ordered through the randomization system. 
A back -up pair of lenses for each dispensed subject will be retained in -office in case a 
non-scheduled lens replacement is required, and the subject already used the two sets of 
lenses that were dispensed at the Screening/Dispensing Visit.  
4.9 Risk Assessment  
Information concerning potential risks associated with the investigational device (as well 
as possible interactions with concomitant medical treatments and risk -to-benefit ratio) 
can be found within the Investigator’s Brochure (IB)/Report of Prior Investigations (ROPI) for the study.  Risks are also summarized within the Informed Consent document.  The assessments required for the study are routinely performed and are standard of care for contact [CONTACT_240368]. The subjects will be informed of any potential study specific 
risks in the ICF or if new risks become apparent during the study. 
5.0 SAFETY AND EFFECTIVENESS  VARIABLES  
Safety and effectiveness endpoints are also shown in  Section  8.1. 
5.1 Safety Variables 
The safety of the rewetting drops will be determined by [CONTACT_89944]: 
• The primary safety endpoint will be slit lamp findings greater than grade 2. 
• Adverse Events will also be evaluated. Information regarding any subject - or 
investigator- reported AEs will be obtained at each follow -up visit. The rate of 
adverse events is not a primary endpoint and is not associated with a predefined 
success criterion.  
5.2 Primary Effectiveness Variables  
Effectiveness of the rewetting drops will be determined by [CONTACT_89944]: 
• Overall comfort  
• Dryness  
5.[ADDRESS_291979] 
lens and care solution use.     
6.0 STUDY METHODS  
6.1 Study Visits  
Refer to APPENDIX A:  for a s chedule of visits and parameters and APPENDIX B:  for 
methods of clinical evaluation .  
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 23 of 72 Prior to enrollment into the study, the Investigator (or designee) will explain the purpose 
of the study, procedures, risks/benefits, and subject responsibi lities to the potential 
participant. The subject’s willingness and ability to meet the follow -up requirements of 
the study will be determined. If the subject chooses to participate in the investigation, written informed consent, including Health Insurance Portability Accountability Act 
(HIPAA) authorization, will be obtained.  The subject and the person obtaining written 
consent will sign and date the IRB-approved ICF.  The Investigator should retain the signed original document in the subject’s record and provide a copy to the subject.  In addition, the applicable privacy regulation requirements must be met. 
6.1.1 Screening/Dispensing Visit  
After obtaining written informed consent, prospective subjects will be screened to 
determine whether they meet the entry cri teria for the study.  
A Screening and Enrollment Log will be provided by [CONTACT_240369]. Once the Screening and Enrollment Log is complete and all data is reviewed and confirmed by [CONTACT_240370] , the Investigator will sign and date the form 
verifying the documented data is correct. The Investigator will retain a copy of the original document for their records and the field monitor will submit the original for 
Sponsor. 
After obtaining written informed consent, prospective subjects will be screened to 
determine whether they meet the entry criteria for the study.  
The Screening/Dispensing Visit will proceed as follows: 
NOTE:  All VA measurements MUST be made using a phoropter.  
a. Enter the subject information on the next available line of the Screening Log. 
b. Collect demographic  and medical history (within 1 year of signing the ICF) and 
concomitant medications. Concomitant medications (as defined for this study) include any medications (systemic and ocular) for conditions taken within [ADDRESS_291980] the following baseline lens/lens care history information and lens wear parameters from the subject:  
− Average number of days per week worn 
− Average daily wearing time, hours per day 
− Average hours of comfortable wear per day  
− Hours lenses worn on the day of this visit  
− Current lens brand, sphere power, base curve and diameter  
− Current lens care products  
d. Perform the following baseline assessments (without lenses; remove the lenses if the subject wore lenses to the visit) :  
− Spherocylindrical refraction  
− High contrast distance best spectacle -corrected visual acuity (BSCVA)  
− Keratometry  
e. Perform a slit lamp examination (without lenses) and r ecord : 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 24 of 72 − Any ungraded finding marked as “P resent ” 
− Any corneal scars  
− Any neovascularization within the central 6 mm of the cornea 
− Any corneal staining 
− Any corneal infiltrate (record details on the APPENDIX C:  Corneal Infiltrates 
Evaluation Form ) 
− Record and sketch any scars and slit lamp findings gre ater than Grade [ADDRESS_291981]’s source document.  
f. Indicate on the Screening and Enrollment Log whether the subject is a “Screen Pass” 
or “Screen Fail.”  Only “Screen Pass” subjects should be randomized in the study.  “Screen Fail” subjects are ineligible and cannot be randomized in the study.  No 
eCRFs shall be completed for “Screen Fail” subjects.  
− If the subject is a “Screen Pass” : Log into ORS to randomize the subject.  Enter 
the subject number from ORS on the Screening and Enrollment Log. 
− If the subjec t is a “Screen Fail” : Log into ORS and indicate the reason for screen 
failure . Enter the subject number from ORS on the Screening and Enrollment 
Log. 
g. If the subject is a “Screen Pass” the Unmasked Designee should then dispense the randomized Study Kit (ref er to Section 4.4.2) to the subject and record the required 
information in the subject’s individual Product Accountability Log.    
h. Dispense two pairs ( one for back up only) of the subject’s habitual contact [CONTACT_240371].  
i. Instruct subject to insert study lenses  and c ollect the following Subjective  
Assessments for the insertion of study lenses using the 0-100 rat ing scales:  
‒ Burning/Stinging Upon Insertion (Rating Scale #1) 
‒ Comfort Upon Insertion (Rating Scale #2) 
‒ Ease of Handling/Insertion (Rating Scale #5) 
j. Unmasked designee will i nstruct,  and view  the subject placing 1-[ADDRESS_291982] the following Subjective 
Assessment s for the instillation of study drops using the 0-100 rating scales: 
‒ Burning/Stinging Upon Drop Instillation (Rating Scale #16) 
‒ Comfort Upon Drop Instillation (Rating Scale #17) 
‒ Vision Upon Drop Instillation (Rating Scale #18) 
k. Record the following into the subject’s source documentation for entry in to EDC: 
− Dispensed lens type (brand), sphere power, base curve and diameter  
− High contrast distance lens VA  
− Over -refraction and distance VA 
− Lens wettability  
− Lens centration  
− Lens movement 
− For each eye, compare the high contrast distance lens VA to the high contrast 
Distance Best Spectacle- Corrected VA obtained at this visit. If th e VA has 
decreased by 5 letters (0.1 logMAR) or more, explain. 
Study [ADDRESS_291983] that:  
− Study K it cartons and its contents  are NOT to be opened in front of any other site 
personnel.    
− The subject should retain all study mate rials (bottles /single- use dispenser s and 
lenses) during the course of the study. 
− Prior to coming to the site for the 1-month, exit or early study termination visits, 
the subject should: (i) place zippered bag containing all used single- use disp ensers  
or mu lti-dose bottles and unused single- use dispensers/bottles  of study rewetting 
drops into their original white carton, (ii) place the carton and all lens cases into 
the opaque subject take -home white drawstring bag, (iii) close the bag, and (iv) 
return it to the unmasked designee.  
m. The Unmasked Designee can dispense the Other Supplies, as needed by [CONTACT_102] 
(refer to Section 4.4.3).    
n. If the Subject was randomized and needs to be exited during this visit, complete the 
Exit Visit as per Section 6.1.4. 
o. Collect/assess all AEs/ADEs, including serious or significant non- serious AEs, since 
consent was signed.  
p. Complete the forms below and transcribe to the eCRFs:   
− Screening/Dispensing Visit Form  
− Exit Visit Form (to be used if the subject is discontinued after a subject ID has 
been assigned in ORS) 
6.1.2 2-Week Follow- up Visit  
The 2-Week Follow-up Visit will proceed as follows: 
NOTE:  All VA measurements MUST be made using a phoropter.  
NOTE:  Study lenses should not be dispensed at this visit unless replacement lenses are required. Lenses 
worn to this visit should be returned to the subject for use until the next scheduled visit.  
NOTE:  If the subject come s to a visit not  wearing lenses due to requiring a replacement and is not 
experiencing any problems, it is preferred to do an Unscheduled Visit for Product Dispensing 
Only and reschedule the 2-Week visit within the visit window. Refer to Un scheduled Visit, 
Section 6.1.5 
NOTE:  If the subject come s to a visit not  wearing lenses and does not require  a replacement , reschedule 
the current visit within the visit window.  
a. If a subject misses the scheduled follow -up visit and cannot be seen prior to the start 
of the visit window for the next scheduled follow -up visit, then the visit is considered 
missed.   
b. Collect the following lens wear parameters from the subject , since last visit: 
− Average number of days per week lenses were worn  
− Average number of times rewetting drops used per day on days when lenses were 
worn  
− Average daily wearing time  
− Average hours of comfortable wear  
− Hours lenses worn on the day of this visit  
Study [ADDRESS_291984] the Symptoms/Complaints  from the subject using the [ADDRESS_291985] any relevant medical treatment information, inc luding any adverse events , use 
of concomitant medications  and/or culture that may have been taken since the last 
visit.  
f. Evaluate the lenses (while on eye) and record the following assessments: 
− Distance lens VA  
− Over -refraction and distance VA 
− Lens wettabili ty 
− Lens discoloration  
− Lens deposits (type, percent and degree) 
− Lens centration  
− Lens movement 
− For each eye, compare the high contrast distance lens VA to the high contrast 
distance lens VA obtained at the Screening/Dispensing Visit. If the VA has 
decreased by 10 letters (0.2 logMAR) or more, explain. 
e. Perform a slit lamp examination  (remove and store the lenses in the appropriate 
disinfecting solution during the exam , either Biotrue multi-purpose solution or [LOCATION_011] 
SIMPLUS Multi -Action Solution ) and r ecord the following in subject source 
documents for entry in to EDC: 
− Any ungraded finding marked as “Present” 
− Any new corneal scars  
− Any neovascularization within the central 6 mm of the cornea 
− Any corneal staining 
− Any corneal infiltrate  (record details on the APPENDIX C:  Corneal Infiltrates 
Evaluation Form )  
− Record and sketch any scars and slit lamp findings greater than Grade [ADDRESS_291986]’s source document.  
g. Return the lenses to the subject to wear until the final study visit.  
h. If the subject needs to exit the study at this visit, complete the Exit Visit as per 
Section  6.1.4. 
i. Complete the forms below and transcribe to the eCRFs.   
− 2-Week Follow- up Visit Form  
− Exit Visit Form (to be used if the subject is discontinued or exited at this visit)  
6.1.3 1-Month Follow -up  
The 1-Month Follow- up will proceed as follows:  
NOTE:  All VA measurements MUST be made using a phoropter.  
NOTE:  If all scheduled visits are performed on time and the subject complete s the 1-Month Visit, the 
Exit Visit will be done at the same time.  
NOTE:  If the subject come s to a visit not  wearing lenses due to requiring a replacement and is not 
experiencing any problems, it is preferred to do an Unscheduled Visit for Product Dispensing 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 27 of 72 Only and reschedule the 1-Month visit within the visit window. Refer to Unscheduled Visit, 
Section 6.1.5.  
NOTE:  If the subject come s to a visit not  wearing lenses and does not require  a replacement , reschedule 
the current visit within the visit window.  
a. Collect the following lens wear parameters from the subject , since last visit : 
− Average number of days per week lenses were worn  
− Average number of times rewetting drops used per day on days when lenses were 
worn  
− Average daily wearing time  
− Average hours of comfortable wear  
− Hours lenses worn on the day of this visit  
b. Collect the Symptoms/Complaints from the subject using the [ADDRESS_291987] any relevant medical treatment information, including any adverse events , use 
of concomitant medications  and/or culture that may have been taken since the last 
visit.  
e. Evaluate the lenses (while on eye) and recor d: 
− Distance lens VA  
− Over -refraction and distance VA 
− Lens wettability  
− Lens discoloration  
− Lens deposits (type, percent, and degree) 
− Lens centration  
− Lens movement  
− For each eye, compare the high contrast distance lens VA to the high contrast 
distance lens VA obtained at the Screening/Dispensing Visit. If the VA has 
decreased by 10 letters (0.2 logMAR) or more, explain. 
f. Perform a slit lamp examination  (remove and store the lenses in the appropriate 
disinfecting solution during the exam, either Biotrue multi-purpose solution or SIMPLUS Multi -Action Solution) and r ecord the following: 
− Any ungraded finding marked as “Present” 
− Any new corneal scars  
− Any neovascularization within the central 6 mm of the cornea 
− Any corneal staining 
− Any corneal infiltrate  (record details on the APPENDIX C:  Corneal Infiltrates 
Evaluation Form )  
‒ Record and sketch any scars and slit lamp findings greater than Grade [ADDRESS_291988]’s source document . 
f. Complete the forms below and transcribe to the eCRFs.   
− 1-Month Follow-up Visit Form 
NOTE:  Do not continue with the Exit Visit until/unless the subject is ready to exit 
the study.  Subjects who require further follow -up at  the conclusion of the 1- Month 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 28 of 72 Follow- Up Visit will be followed according to the AE and/or Unscheduled Visit 
Section until the AE is resolved or stabilized  
6.1.4 Exit Visit  
The Exit Visit will proceed as follows:  
a. Indicate status of the subject on the Exit Visit Form. If the status is “Discontinued”  
(dispensed or non- dispensed),  indicate the (one) PRIMARY exit reason for each eye 
on the Exit Visit Form.  
b. Collect any relevant medical treatment information, including any adverse events , use 
of concomitant medic ations and/or culture that may have been taken since the last 
visit.  
c. For all subjects, complete an exit ocular examination without lenses on the eyes. 
Collect the following assessments:  
− Spherocylindrical refraction  
− High contrast distance best spectacle -corrected visual acuity (BSCVA)  
− Keratometry  
d. For each eye:  
− Compare the final visit high contrast distance BSCVA to the high contrast distance BSCVA obtained at the Screening/Dispensing Visit. If the VA has decreased by 10 letters (0.2 logMAR) or more, explain. 
− Compare the final visit keratometry readings to the Screening/Dispensing Visit keratometry readings. If there is a change of 1.[ADDRESS_291989] all dispensed lenses (worn and unworn) and Study Kit (s) from the subject and 
return all to the Sponsor or designee using the return materials provided (refer to Section 4.5). Worn lenses will be returned in lens cases filled with Bausch + Lomb 
Sensitive Eyes Saline Solution.     
g. Complete the forms below and transcribe to the eCRFs.   
− Exit Visit Form  
  
6.1.[ADDRESS_291990] visit within the scheduled visit interval will be used for completion of the protocol required  
scheduled visit eCRF. Data from any additional visits within a scheduled visit interval will be captured on an Unscheduled Visit eCRF.  
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 29 of 72 Subjects who require further follow -up on an AE/SAE upon discontinuation or at the 
conclusion of the 1-Month Follow -Up Visit will be followed according to the AE and/or 
Unscheduled Visit Section as necessary. At these follow- up visits, the subject should 
remove contact [CONTACT_13276] s/he may be wearing. Assessments will be performed  according to 
the investigator’s  judgement. The Investigator is required to follow the subject until the 
condition no longer warrants further follow-up for study purposes. 
NOTE: All VA measurements MUST be made using a phoropter.  
a. Determine the reason for the Unscheduled Visit.  
− If the visit is to dispense study materials only and the subject is not experiencing 
any problems, refer to Product Dispensing Only, Section [IP_ADDRESS].   
− If the subject is experiencing problems, proceed  with the Unscheduled Visit 
assessments as needed, below .  
b. Collect the following lens wear parameters from the subject , since last visit : 
− Average number of days per week lenses were worn  
− Average number of times rewetting drops used per day on days when lenses were 
worn  
− Average daily wearing time  
− Average hours of comfortable wear  
− Hours lenses worn on the day of this visit  
c. Collect the Symptoms/Complaints from the subject using the [ADDRESS_291991] any relevant medical treatment information, including any adverse events , use 
of concomitant medications  and/or culture that may have been taken since t he last 
visit.  
f. If the subject did not come to the visit wearing one or more study lenses, go to step g. 
Otherwise, evaluate the lenses (while on eye) and record the following assessments:  
− Distance lens VA  
− Over -refraction and distance VA 
− Lens wettability  
− Lens discoloration  
− Lens deposits (type, percent and degree) 
− Lens centration  
− Lens movement 
− For each eye, compare the high contrast distance lens VA to the high contrast 
distance lens VA obtained at the Screening/Dispensing Visit. If the VA has decreased by 10 letters (0.2 logMAR) or more, explain. 
g. Perform a slit lamp examination  (remove and store the lenses in the appropriate 
disinfecting solution during the exam, either Biotrue multi-purpose solution, or SIMPLUS Multi -Action Solution) and r ecord the followi ng: 
− Any ungraded finding marked as “Present” 
− Any new corneal scars  
− Any neovascularization within the central 6 mm of the cornea 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 30 of 72 − Any corneal staining 
− Any corneal infiltrate  (record details on the APPENDIX C:  Corneal Infiltrates 
Evaluation Form )  
− Record and sketch any scars and slit lamp findings greater than Grade [ADDRESS_291992]’s source document.  
g. If additional study rewetting drops are  require d at this visit, log into ORS to dispense 
a new Study Kit (refer to Section 4.4.2) to the subject according to ORS  and InForm  
and record in the Product Accountability Log. 
h. If an unscheduled lens replacement is required at this visit  in addition to performing 
assessments,  dispense a new pair of subject’s habitual lenses, record in Lens 
Accountability Log and collect the following information: 
− Primary (one) reason for replacement 
− Dispensed lens type (brand), sphere power, base curve , and diameter  
i. If Study Lenses were replaced, collect the worn lenses from the subject  and place in 
lens case with Sensitive Eye Saline Solution and place the lens case in zippered bag 
with worn lens labels provided. Record in Lens Accountability Log. 
j. If the subject needs to exit the study at this visit, complete the Exit Visit as per  
Section  6.1.5. 
k. Complete the form(s) listed below and transcribe to the eCRF as appropriate.   
− Unscheduled Visit Form 
− Exit Visit Form (to be used if the subject is discontinued or exited at this visit)  
 Product Dispensing Only (Part of the Unscheduled Visit - used only if lens 
and/or rewetting drop replacement is needed) 
If a subject is only seen for an unscheduled lens or study drop replacement, a complete 
exam is not required as long as the subject is not experiencing any problems. 
NOTE: For study drop replacement, an unmasked designee MUST dispense the study drops to the subject 
to ensure the Investigator remains masked.   
a. If study lenses and/or drops are dispensed, collect the following information in the 
source document and transcribe to the Product Dispensing Only eCRF Form: 
− Visit date  
− Subject ID number  
− Subject initials  
− Primary reason for replacement  
b. Record Study Kit  dispensed on the Product Accountability Log.  Record lenses 
dispensed on the Lens Accountability Log.  
 If any assess ment is performed, then an Unscheduled Visit Form must be 
completed instead of a Product Dispensing Only Form. 
6.1.6 Missed Visits  
Missed Visits will be handled as follows:  
Study [ADDRESS_291993] been exited. Sponsor approval is required prior to IRB 
notification.  
6.2.1 Early Study Termination/Suspension 
If during the study it becomes evident to the Sponsor that the study should be stopped prematurely or placed on hold, the study will be terminated, and appropriate notification 
will be given to the Investigator(s), IRBs, and FDA, as applicable. Bausch + Lomb will instruct the Investigators to stop/restart dispensing study materials and will arrange for study closeout, if applicable, at each site.   Any subjects with ongoing Adverse Events at 
the time of premature study termination or hold will be followed by [CONTACT_737], as outlined in the Safety Management Plan. 
6.3 Concomitant Medications/Therapy  
Other contact [CONTACT_240372].  
Ocular medications or systemic or topi[INVESTIGATOR_145903], in the Investigator’s opi[INVESTIGATOR_1649], 
could potentially affect ocular physiology or lens performance are also prohibited, unless medically necessary during the  course of the study.  Any medications that have been 
taken in the past [ADDRESS_291994] who does not follow instructions to a degree that, in the Sponsor or Investigator’s opi[INVESTIGATOR_1649], jeopardizes the subject’s well -being or the validity of the study must be 
discontinued. 
6.[ADDRESS_291995]’s condition requires that they be discontinued from the study. 
According to t he Device Investigator Agreement, all investigators participating in this 
study agree to conduct the study in accordance with the relevant, current protocol and 
agree to only make changes in a protocol after being notified by [CONTACT_1034], except when necessary to protect the safety, rights, or welfare of subjects.    
Study [ADDRESS_291996](s) and/or the quality or integrity of 
data.  The Site Corrective Action Plan will outline the deviation and the site’s corrective and/or remedial actions.  Decisions regarding critical deviations that merit investigator disqualification and site closure will be made by [CONTACT_240373].  
7.0 ADVERSE EVENTS  
7.1 Adverse Event Definitions 
For the purposes of this study, reportable adverse events (AEs) include ocular AEs and non-ocular serious adverse events (SAEs). All AEs will be classified first for seriousness 
and significance and then as to whether or not they are an adverse device effect (ADE), an anticipated serious adverse device effect (ASADEs) or an unanticipated serious adverse device effect (UADEs). AEs, ADEs, ASADEs, UADEs, SAEs, Significant Non -
Serious AEs and Non- Significant Non -Serious AEs are defined as follows:  
7.1.1 Adverse Event  (AE)  
Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in a subject, user, or other persons, whether or not related to the investigational medical device. This definition inc ludes 
events not related to the investigational medical device, comparator, or the procedures involved. For users or other persons, this definition is restricted to events not related to investigational medical devices.  
Throughout the course of this study all efforts will be made to remain alert to reportable 
AEs. If an AE occurs the first concern will be the safety of the subject and appropriate medical intervention will be made. 
AEs should be first assessed for seriousness and significance and then differ entiated for 
device related and non- device related.  
All reportable AEs occurring after signing of informed consent and through the subject’s 
end of participation in the study must be reported. All reportable AEs must be followed until the event resolves o r stabilizes.  
Applicable AEs should be photo documented and communicated to the Medical Monitor in electronic form.  
7.1.[ADDRESS_291997] (ADE)  
An ADE is an AE that is assessed to be related to the use of an investigational medical device. This definition includes AEs resulting from insufficient or inadequate instructions for use; deployment, implantation, installation, or operation; or any malfunction of the investigational medical device. This definition also includes any event resulting from use error or from intentional misuse of the investigational medical device.  
 Anticipated Serious Adverse Device Effect (ASADE)  
An ASADE is an ADE that first meets the serious criteria (see Section 7.1.3 ) or 
significant non- serious criteria (see Section 7.1.4) and which, by [CONTACT_5942], incidence, 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 33 of 72 severity or outcome, has been previously identified in the investigational plan or 
application (including a supplementary plan or application) and/or in the risk analysis report. ASADEs include:  
 
• Corneal Ulcer (infectious or non-infectious)  
• Keratitis  
• Sensitivity to light (photophobia)  
• Excessive eye secretions including mucopurulent discharge  
• Blurred vision, rainbows or halos around objects  
• Poor visual acuity (reduced sharpness of vision)  
• Moderate to severe eye pain not relieved by [CONTACT_240374] (UADE)  
An UADE is an ADE that first meets the serious criteria (see Section 7.1.3) and has an 
effect on health or safety or any life- threatening problem or death caused by, or 
associated with, a device if that effect, problem or death was not previously identified in nature, severity or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of subjects.  
7.1.3 Serious Adverse Event (SAE)  
An AE that:  
o Led to death; 
o Led to serious deterioration in the health of the subject, that resulted in: 
‒ A life -threatening illness or injury; or  
‒ A permanent impairment of a body structure or a body function (e.g., 
blindness); or  
‒ Inpatient or prolonged hospi[INVESTIGATOR_059]; or 
‒ Medical or surgical intervention to prevent life -threatening illness or 
injury or permanent impairment to a body structure or a body function; 
o Led to fetal distress, fetal death, or a congenital abnormality or birth defect. 
Note: A planned hospi[INVESTIGATOR_272] a pre-existing condition, or a procedure 
required by [CONTACT_760], without serious deterioration in health, is not considered 
an SAE. 
Serious adverse events are also those events that result in, or have potential to cause, 
either permanent impairment of an ocular function or damage to an ocular structure and 
may necessitate medical or surgical intervention.  
Serious adverse events may include any hazardous, sight -threatening condit ions 
occurring after exposure to the test article, including the following: 
• A presumed infectious ulcer (defined as a progressive erosion of the corneal tissue). For the purposes of reporting, this includes: 
o Central or para -central location;  
o Penetration o f Bowman’s membrane; 
o Infiltrate ≥2 mm diameter;  
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 34 of 72 o Associated with iritis;  
o Associated with any increase in intraocular pressure;  
o Culture positive for microorganisms; 
o Increasing size or severity at subsequent visits;  
NOTE: Signs of a presumed infectious corneal ulcer may include irregular focal 
infiltrates, active lesions with raised edges, significant diffuse infiltration, 
anterior corneal to mid-stromal involvement, erosion with overlying staining, 
conjunctival and lid edema, anterior chamber reaction (iritis), and severe bulbar and limbal redness. Symptoms associated with a presumed infectious ulcer 
(microbial keratitis) may include pain of rapid onset, severe redness, purulent or 
mucopurulent discharge, tearing, and photophobia.
 
• Any central or paracentral (within 6 mm of cornea) corneal event that results in 
permanent opacification (such as corneal scar or vascularization);  
• Any serious adverse ophthalmic events including hypopyon and/or hyphema;  
• Any neovascularization within the central 6 mm of the cornea;  
• Permanent loss of ≥2 lines of BSCVA;  
• All cases of iritis.  
7.1.4 Significant Non -Serious Adverse Events  
A significant non- serious adverse event is an AE that does not meet the serious criteria, is 
considered significant by [CONTACT_1034], and require s expedited reporting. These events 
include:  
• Peripheral non-progressive non-infectious corneal ulcers;  
• All symptomatic corneal infiltrative events;  
• All cases of corneal staining greater than or equal to Grade 3;  
• A temporary loss of two or more lines of BSCVA (for greater than or equal to 2 weeks);  
• Neovascularization cases Grade 2 or greater;  
• Any ocular event that necessitates temporary lens discontinuation of greater than or equal to 2 weeks.  
7.1.5 Non-Significant Non -Serious Adverse Events  
A non- significant non- serious adverse event may include but are not limited to the 
following and does not require expedited reporting: 
• Bacterial Conjunctivitis;  
• Viral Conjunctivitis; 
• Allergic Conjunctivitis;  
• Corneal Edema;  
• Contact [CONTACT_240375][INVESTIGATOR_19534]; and,  
• Loss of Contrast Sensitivity 
Study [ADDRESS_291998] of care. 
For purposes of this study, the Sponsor requests that cultures should be obtained in cases 
of corneal ulcer or suspected ocular infection, unless medically contraindicated. Cultures should be taken from the cul -de-sac, lower eyelid margin, and the corneal lesion (if 
applicable). The required culturing techniques are outlined in APPENDIX D: . 
When a culture is obtained, the contact [CONTACT_240376]. 
Microbial data generated from returned subject supplies (e.g. lenses, lens cases, and/or 
lens case solutions) are for information only. Because microbes may be introduced into subject supplies during use, recovery of microbes from returned subject supplies cannot be presumed to indicate etiology or direction of organis m transmission.  
The ocular cultures, along with the associated contact [CONTACT_145924], will be sent to the local clinical laboratory designated by [CONTACT_240377]. The clinical laboratory will report the culture results to the Investigator who will record the results in the eCRF.  
7.[ADDRESS_291999] determine if the event is serious (refer to Section 7.1.3 for criteria) and/or signific ant (refer to Section s 7.1.4 and 
7.1.5) and then assess the severity of symptoms and the relationship of the event to the study device using the following guidelines: 
7.3.1 Severity  
• 
Mild:  Subject awareness of a sign or symptom that is easily tolerated, requires no 
treatment, and does not interfere with su bject’s daily activities.  
• Moderate: Subject awareness of a sign or symptom which may be a low level of 
concern to the subject and may interfere with daily activities but can be relieved by 
[CONTACT_119106].  
• Severe: A sign or symptom that interrupts the subject’s daily activity and re quires 
systemic therapy or other treatment 
7.3.2 Relationship to Study Device and/or Rewetting Drops  
• Related: There is at least a reasonable possibility that the AE is related to the study device (study solution) and/or rewetting drops. Reasonable possibility me ans that 
there is evidence to suggest a causal relationship or association between the study device and/or rewetting drops and the AE. Also referred to as an ADE.  
• Not related : There is little or no reasonable possibility that the AE is related to the 
study  device (study solution) and/or rewetting drops. This assessment implies that 
the AE has no evidence to suggest either a causal relationship or association to the 
study device and/or rewetting drops and a more likely or certain alternative 
etiology exists.  
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 39 of 72 [𝜋𝜋𝑆𝑆]) is greater than or equal to 0.05 (5%). The alternative hypothesis ( 𝐻𝐻1) is that the 
differen ce is less than 0.05 (5%).  
𝐻𝐻0: 𝜋𝜋𝑇𝑇−𝜋𝜋𝑆𝑆≥0.05 
𝐻𝐻1: 𝜋𝜋𝑇𝑇−𝜋𝜋𝑆𝑆< 0.05  
8.2.2 Overall Comfort 
The null hypothesis ( 𝐻𝐻0) is that the difference in mean overall comfort (test group mean 
[𝜇𝜇𝑇𝑇] minus standard group mean [ 𝜇𝜇𝑆𝑆]) is less than or equal to negative five points. The 
alternative hypothesis ( 𝐻𝐻1) is that the difference is greater than negative five points.  
𝐻𝐻0: 𝜇𝜇𝑇𝑇−𝜇𝜇𝑆𝑆≤ − 5 
𝐻𝐻1: 𝜇𝜇𝑇𝑇−𝜇𝜇𝑆𝑆>−5 
8.2.3 Dryness 
The null hypothesis ( 𝐻𝐻0) is that the difference in mean dryness score (test group mean 
[𝜇𝜇𝑇𝑇] minus standard group mean [ 𝜇𝜇𝑆𝑆]) is less than or equal to negative five points. The 
alternative hypothesis ( 𝐻𝐻1) is that the difference is greater than negative five points.  
𝐻𝐻0: 𝜇𝜇𝑇𝑇−𝜇𝜇𝑆𝑆≤ − 5 
𝐻𝐻1: 𝜇𝜇𝑇𝑇−𝜇𝜇𝑆𝑆>−[ADDRESS_292000] deviations and proportions were obtained from Bausch + Lomb 
Study #872.[ADDRESS_292001]’s eyes will be independent. This is a standard assumption for contact [CONTACT_240378].  
The recommended minimum sample size is [ADDRESS_292002] group subjects per lens stratum. Therefore, with eight strata the targeted completed sample size will be ([ADDRESS_292003] subjects/stratum + 20 Control subjects/stratum) x 8 strata = 320 subjects (assuming sufficient statistical power is provided by [CONTACT_240379]).  
Sample size calculations were completed using nQuery Advisor® 7.0 software.  
8.3.1 Slit Lamp Findings 
In Study 872, the proportion of eyes with slit lamp finding greater than grade 2 at any 
follow up visits was 0.005. With 320 eyes (160 subjects) in each group, the upper limit of the observed one- sided 95% confidence interval will be expected to be less th an 0.05 
with 99% power when the Standard proportion, π
S, is 0.[ADDRESS_292004] deviation of overall comfort ratings averaged over all visits was 13.9 units. When the sample size in each group is 320 eyes (160 subjects), a two group 0.[ADDRESS_292005] 99% power to reject the null hypothesis that the te st 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 40 of 72 is not non- inferior to the control (the difference in means, µT - µ S, is -5 or farther from 
zero in the same direction) in favor of the alternative hypothesis that the test is non -
inferior, assuming that the expected difference in means is [ADDRESS_292006] deviation of dryness ratings averaged over all visits was 13.9 
units. When the sample size in each group is 320 eyes (160 subjects), a two group 0.[ADDRESS_292007] 99% power t o reject the null hypothesis that the test is not non -
inferior to the control (the difference in means, µ
T - µS, is - 5 or farther from zero in the 
same direction) in favor of the alternative hypothesis that the test is non -inferior, 
assuming that the expected difference in means is [ADDRESS_292008] deviation is 13.9. 
8.3.4 Overall Power  
If the primary endpoints are independent, the overall power of the study is 99% x 99% x 
99% = 97%. 
8.3.5 Enrollment Target  
The desired completed sample size is 160 subjects per  group. Allowing for up to 13% 
losses, the enrollment target in each treatment group will be approximately  ⌈160 ÷ (1−
0.13)⌉=184 subjects. The total enrollment target will be approximately 2 x 184 = 368 
subjects (736 eyes).  
8.4 Randomization 
Subjects will be randomized to one of two treatment arms in a 1:[ADDRESS_292009] drops 
or Control drops for the duration of the study.  Randomization will be managed using ORS.  The randomization will be stratified by [CONTACT_240380].  The lens group wi ll be determined by [CONTACT_748]’ habitual lens material at 
Screening/Dispensing  and will be one of the groups shown in Table 1: Lens Groups
  
(page 13).  
Efforts will be made to enroll subjects in at least four of the lens strata within each site to 
minimize confounding between site and lens strata.  It should be noted that while the 
target enrollment for each lens strata is approximately 40 subjects (approximately 20 per treatment arm), some lens strata may be difficult to enroll.  
An unmasked statistician who is not otherwise involved in the trial will create the randomization schedule. 
8.5 Study Populations  
8.5.1 Intent- to-Treat (ITT) Population  
The ITT Population will consist of all randomized subjects and both of their eyes. 
Subjects will be included in ITT Population summaries according to the treatment group to which they were randomly assigned. 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 41 of 72 8.5.2 Per Protocol (PP) Population  
The PP population will be the primary population used for analysis of the primary 
effectiveness endpoints. The PP Population will consist of all ITT Population subjects without important (major) protocol deviations for subject level summaries and, for eye level summaries, both of their eyes. Important protocol deviation categories are defined in Section 8.6.4. Subjects will be included in PP Population summaries according to the 
treatment group to which they were randomly assigned.  Membership in the PP population will be determined prior to study unmasking. 
8.5.[ADDRESS_292010] treatment group. 
8.6 Statistical Analysis  
8.6.1 Methods of Analysis  
 General Methods 
Continuous data will be summarized using descriptive statistics: sample size, mean, 
standard deviation, median, minimum and maximum. Categorical data will be presented using the total counts for each category and corresponding percentages. The denominator for each percentage will be the number of subjects or eyes with non -missing data at the 
given visit for each respective study treatment, unless otherwise indicated.  
As is customary for contact [CONTACT_240378], eyes will be treated as independent sampling units in eye level analyses unless otherwise noted.  
Further details will be provided in a separate statistical analysis plan which will be 
completed and approved prior to unmasking of the treatment assignments. 
 Graded Slit Lamp Findings  
At each follow -up visit, graded slit lamp findings will be assessed for each eye using 
Grades [ADDRESS_292011] to findings greater than grade 2 at any visit (Absent, Present). Missing data will not be imputed. Greater than grade 2 finding s 
(Absent, Present) will be summarized at the eye level by [CONTACT_240381] a table. A one- sided upper 95% confidence limit 
around the difference in “Present” proportions between the test and control trea tment 
groups will be constructed using the Newcombe -Wilson score method.
2 If the upper 
confidence limit is less than 5.0%, then the null hypothesis that the test solution is not non-inferior will be rejected, and the test solution will be statistically suc cessful in this 
outcome. 
 Overall Comfort 
At each follow -up visit, overall comfort will be assessed for each eye on a scale from [ADDRESS_292012] favorable response. For each eye, mean overall comfort 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 42 of 72 over all follow -up visits will be co mputed as the average of the non- missing values over 
all scheduled follow -up visits. Missing data will not be imputed for the primary analysis. 
Mean overall comfort over all follow -up visits will be summarized at the eye level by 
[CONTACT_240382] a table. A one -
sided lower 95% confidence limit around the difference in means between the test and 
control treatment groups, computed using an analysis of variance model including the fixed factor of treatme nt and the fixed blocking factor of site, will be displayed. If the 
lower confidence limit is greater than - 5, then the null hypothesis that the test solution is 
not non- inferior will be rejected, and the test solution will be statistically successful in 
this outcome.  
As a sensitivity analysis, the ITT Population will be analyzed for this endpoint. 
Summaries by [CONTACT_139679] a confidence interval around the difference in means will be provided as described above using the available data. Twenty imputations of missing overall comfort data will be produced by [CONTACT_240383] (MCMC) method. The variables used to create the imputed datasets will be the overall comfort scores observed at each scheduled visit. The differences and standard errors estimated by [CONTACT_240384]. 
 Dryness 
At each follow -up visit, dryness will be assessed for each eye on a scale from [ADDRESS_292013] Discontinuation 
The reasons for study discontinuation will be summarized by [CONTACT_240385]. Details of discontinued eyes will be also listed by [CONTACT_3148]. 
8.6.4 Protocol Deviations 
Important (major) protocol deviations will be summarized by [CONTACT_240386] a table.  
Categories of important protocol deviations will include the following, which will be 
deriv ed via data entered on the case report forms.  
• Ineligibility  
• Not dispensed study treatment 
• Mis-randomization 
• Dispensing of the incorrect study treatment 
• Dispensing and use of lenses from the incorrect lens group 
• Use of medications that could potentially aff ect any of the primary effectiveness 
endpoints 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 43 of 72 • Failure to comply with the procedures used to assess the primary effectiveness 
endpoints, such as missing the scheduled visit or failing to complete the procedure in accordance with instructions  
Additional important protocol deviation categories may be added prior to unmasking. 
Important (major) protocol deviations will also be displayed in a listing.  
8.6.[ADDRESS_292014] be allowed to visit all study site locations to assess the data,  
quality, and study integrity in a manner consistent with applicable health authority 
regulations and the procedures adopted by [CONTACT_1034].  
Prior to the start of the study, representatives  of the Sponsor (or designees) will review 
the protocol, eCRF, regulatory obligations, and other material or equipment relevant to 
the conduct of the study with the Investigator/Sub- Investigator and relevant study site 
personnel.  
Monitoring visits and telephone consultations will occur as necessary, or per the 
monitorin g plan, during the course of the investigation to verify the following: 
• The rights and well-being of subjects are protected. 
• This clinical investigation is being conducted in accordance with 21 CFR Parts 11, 50, 54, 56, and 812. The protocol was developed with consideration of the 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 44 of 72 provisions in: ISO [ZIP_CODE]-1:2011 Clinical investigation of medical devices for 
human subjects – Part 1:  General requirements; [ZIP_CODE] -2:2011 Part 2:  Clinical 
investigation of medical devices for human subjects – Part 2:  Clinical investigational plan; ISO [ZIP_CODE]:2012 Ophthalmic Optics – Contact [CONTACT_224068] – Guidance for clinical investigations; ICH GCP and applicable local regulations. The Sponsor intends to register this clinical trial with the public data base https://ClinicalTrials.gov.  
• The integrity of the data, including adequate study documentation. 
• The facilities remain acceptable.  
• The Investigator and site personnel remain qualified and able to conduct the study. 
• Test article accountability  
During the course of the study, if the Sponsor determines that an Investigator is not 
compliant with the protocol and/or applicable regulatory requirements, the Sponsor will take action to secure compliance. In addition, the Sponsor may terminate the Investigator ’s participation in the study if appropriate, or if the Investigator remains  
non-compliant despi[INVESTIGATOR_240342]’s actions.  
Full details for site monitoring procedures are covered in the study [ADDRESS_292015]’s 
record (source documentation) in real time as it is collected. Source documentation consists of original subject documents, as well as data and records with information relevant to the subject and his/her participation in the study.  
Examples of source documents include hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory notes, memoranda, signed ICF, evaluation checklists, recorded data from automated instruments, copi[INVESTIGATOR_12607], and information initially recorded in an electronic format. Source documentation worksheets may be provided by [CONTACT_240387].  
Subject- completed for ms are also considered to be source data. Only subjects are to 
record information on subject -completed forms. In no instance should an Investigator or 
study site personnel record any data or make changes to subject -completed forms. The 
Investigator or designee should review subject -completed forms during study visits for 
completeness and accuracy. If an entry is found to be illegible or a mistake is found (eg, 
incorrect year was recorded), the subject should be instructed to edit the entry by [CONTACT_740] a sing le line through the original entry, entering the new information, and dating and 
initialing the change.    
9.[ADDRESS_292016] data required by [CONTACT_240388]. 
The Investigator a nd his/her study site personnel will be responsible for completing the 
eCRFs. The Investigator is required to verify that all of the requested information is 
accurately recorded on the eCRFs by [CONTACT_240389]. All information requested o n the eCRFs needs to be supplied, including subject identification and initials, 
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 45 of 72 date(s), assessment values, etc., and any omission or discrepancy will require 
explanation. All information on eCRFs must be traceable to source documents.  
The study monitor will be responsible for reviewing and verifying the data recorded on 
the eCRFs per the study Monitoring Plan, utilizing the original source documentation and 
will query discrepant findings. The Investigator and study site personnel will be responsible for answering all queries.  
Details regarding procedures used for data review, database cleaning and issuing and resolving queries are provided in the study [ADDRESS_292017] retain essential documents indefinitely after the completion of the 
study, unless otherwise notified by [CONTACT_1034]. The Investigator agrees to adhere to the document retention procedures when signing the protocol Inve stigator Statement of 
Approval.   
Essential document s include but are not limited to the following: 
• IRB approvals for the study protocol, all amendments, ICF(s), and advertisements 
• IRB annual study review 
• IRB correspondence and reports (eg, AE reports, protocol deviations, and safety 
updates) 
• Regulatory doc uments (eg, financial disclosure and delegation of authority forms) 
• All source documents  
• Archive of eCRFs  
• Subject’s signed ICF  
• Device Investigator Agreement  
• Accountability records for the test article  
• Correspondence from and to the Sponsor 
• Any other documents relevant to the conduct of the study 
In the event that  study records are transferred to another location, the Investigator will 
provide notice of such transfer in writing to Sponsor. 
9.[ADDRESS_292018] an inspection (during 
the study or after its completion). If an inspection is requested by a regulatory authority and/or IRB/EC, the Investigator must inform the Sponsor immediately that this request has been made.  
Study [ADDRESS_292019]/Ethics Committee Approval 
The Investigator should ensure their participation in the study, in addition to the protocol, 
subject recruitment materials (written information or materials including web pages, radio advertisements, television spots, or written text developed to encourage subject enrollment) and the ICF to be used in this study are approved by [CONTACT_239789], or if not using their institution's IRB, approved by [CONTACT_240390]. Documentation of IRB approval of the study protocol 
and informed consent must be provided to the Sponsor prior to initiation of the study. In addition, the Investigator must ensure that the reviewing IRB has provided approval for any protocol amendments prior to implementation. If the amendment necessitates a 
revision to the ICF, the Investigator should ensure the revised form is also submitted to and approved by [CONTACT_240391].  
9.7  Publication of R esults  
All study data generated as a result of this study will be regarded as confidential, until 
appropriate analysis and review by [CONTACT_239792](s) are completed. The results of the study may be published or presented by [CONTACT_737](s) after the review by, and in consultation and agreement with the Sponsor, and such that confidential or proprietary information is not disclosed. 
Prior to publication or presentation, a copy of the final text should be forwarded by [CONTACT_122696](s) to the Sponsor or its designee, for comment. Such comments shall aim to 
ensure the scientific integrity of the proposed publications and/or presentations and ensure that the data and material referring to Bausch & Lomb Incorporated product s and 
activities receive fair, accurate, and reasonable presentation.  
The Sponsor may also choose to submit the results of this study for publication. 
9.[ADDRESS_292020] into the 
study. The Principal Investigator (or Sponsor/CRO on behalf of the Principal Investigator) is responsi ble for informing the IRB of any amendment to the protocol as 
per local requirements.   Any additional requirements imposed by [CONTACT_240392].  
9.8.[ADDRESS_292021]’s signed informed consent must  be obtained before conducting any study 
related procedures. The original must be filed by [CONTACT_3878] . A copy of the 
signed Informed Consent Form should be given to the subject. If modifications are made 
to the Informed Consent Form, the new version must be approved by [CONTACT_1201].  The new 
version of revised Informed Consent Form(s) must be reviewed and signed by [CONTACT_240393] 
(if required by [CONTACT_1201]) and new subjects at the first opportunity after approval by [CONTACT_1201].  
                 
 
        
Study 952 - Protocol  
Amendment 2, December 9, 2019   Page 48 of 72 10.0 REFERENCES  
1 Bausch & Lomb Incorporated Study 872 ‘A Safety and Effectiveness Study of a New 
Contact [CONTACT_240394]’ Final Clinical Study Report, 
(Version 1, 14MAR2016)  
2 Newcombe RG (1988) Interval estimation for the difference between independent 
proportions: comparison of eleven methods.  Statistics in Medicine 17:873-890. 
Study 952 - Protocol  
Page B-1 of 72 
Amendment 2, December 9, 2019  APPENDIX B:  METHODS OF CLINICAL EVALUATION  
Maintenance and calibration of the equipment relevant to study assessments must be  
appropriately performed and documented by [CONTACT_3878] , where applicable .  
Any changes to the procedures described in this appendix will be provided under separate 
cover. 
1.0  Visual Acuity/Refraction  
It is essential that a standard procedure be used to obtain VA measurements. The VA and 
refraction measurements should be obtained by a physician, optometrist, or trained technician. One standard logMAR chart , high 90% contrast, with Sloan letters will be 
used to obtain the VA measurements in this study. The following VA equipment from Precision Vision, Inc . will be used in this study: 90% High Contrast 6.5 feet (2.0 meters) 
testing distance Translucent Chart (CAT. NO. 2 103-2), and the Precision Vision Small 
Illuminator Cabinet (CAT. NO. 914). 
1.[ADDRESS_292022]’s eyes to the logMAR 
chart is 6.5 feet (2.0 meters). The chart should be at eye level for the subject. The 
logMAR charts have two alternative letter sequences from 28 letters (0.3 logMAR) to  
62 letters ( -0.3 logMAR). It is recommended that one letter sequence i s used for the right 
eye, and the second letter sequence is used for the left eye, to minimize learning effects at 
each visit. Care should be taken to completely occlude the eye not being measured.  
Since the test distance of the chart is not at optical infinity, refractive power 
compensation is required to simulate optical infinity. The VA should be measured through the phoropter using the distance refractive correction with the addition of  
+0.[ADDRESS_292023] distance of 6.5 feet ( 2.0 meters).  
If all letters are correctly identified on any given line, then the subject is encouraged to read the next smaller line. When the subject says they cannot read a letter, they should be required to guess. A maximum effort should be made to identify each letter. A scoring sheet for each eye is provided to keep track of the letters correctly identified  by [CONTACT_240395] “X” over the incorrectly identified letter . The subject continues reading down the chart 
to the last letter of a given line, until th e subject has missed [ADDRESS_292024] to be consecutive. 
Study 952 - Protocol  
Page B-2 of 72 
Amendment 2, December 9, 2019  1.3 Recording and Scoring logMAR Values 
Using the Sponsor supplied recording/scoring sheet, an example of which is shown 
below, the tester will record the actual VA measure.  
The number of letters CORRECT will be recorded on the rec ording/scoring sheet in the 
far right box on the corresponding line. The lines will then be added up and the 
“TOTAL” number of letters correctly identified will be recorded on the recording/scoring 
sheet. The “TOTAL” is the number that will be entered onto the eCRF.  
Example of Distance VA:  
In the example below, all letters in lines [ADDRESS_292025] 
would be considered complete. In this example, the total letters correctly identified is 42. This number is recorded in the space marked “TOTAL” and also  recorded on the eCRF. 
 
       

Study 952 - Protocol  
Page B-3 of 72 
Amendment 2, December 9, 2019  2.0  Slit Lamp Examination  
The following parameters will be assessed during the Slit Lamp Examination (without 
lenses):  
Epi[INVESTIGATOR_223993]  
 0 -  None: No epi[INVESTIGATOR_32468] -epi[INVESTIGATOR_32469]. Normal transparency.  
 1 -  Trace: Barely discernible localized epi[INVESTIGATOR_32468] -epi[INVESTIGATOR_32469].  
 2 - Mild: Faint but definite localized or generalized epi[INVESTIGATOR_32469].  
 3 - Moderate: Significant localized or general epi[INVESTIGATOR_32469].  
 4 - Severe: Definite widespread, ep ithelial cloudiness giving dull glass 
appearance to cornea, or numerous coalescent buliae.  
Epi[INVESTIGATOR_223996]  
 0 - None: No microcysts seen using retroillumination.  
 1 - Trace: Fewer than 50 microcysts over central or para- central cornea. No 
overlying staining or surface anomaly. 
 2 - Mild: More than 50 microcysts over central or paracentral cornea. No overlying staining or surface anomaly. 
 3 - Moderate: More than 50 microcysts, tending to be coalescent and accompanied by [CONTACT_240396]. 
 4 - Severe: Numerous, dense, coalescent microcysts accompanied by [CONTACT_240397]. 
Corneal Staining  
Corneal staining must be assessed after the instillation of fluorescein. If needed, a  
Wratten Gel Filter will be provided  by [CONTACT_240398]. 
The Wratten Gel Filter must be used as a barrier filter in the observation pathway, in combination with the cobalt blue filter.  
 0 - None: No fluorescein staining. 
 1 - Trace: Minimal superficial staining or stippling, and non- coalescing. 
Includes superficial foreign body staining. 
 2 - Mild: Lightly coalescent or diffuse punctate staining, with no stain 
diffusion into stroma. 
 3 - Moderate: Significant or densely coalescent punctate st aining, including 
slight diffusion of stain into stroma.  
 4 - Severe: Severe abrasion or erosion with loss of epi[INVESTIGATOR_240343]. Marked and rapid diffusion of stain into stroma. 
 
    
Study 952 - Protocol  
Page B-4 of 72 
Amendment 2, December 9, 2019   
New corneal scar or pre-existing corneal scar (Record for both OD and OS)  
Absent or Present  
Location: Check all that apply 
  Central (central 6 mm, 3 mm from corneal center)  
  Nasal  
  Inferior  
  Temporal 
  Superior 
Size: X.X (mm)    Draw:  
  
Limbal Injection  
 0 - None: No hyperemia present. Normal appearance of limbal vessels 
including prominent limbal vascular arcades.  
 1 - Trace: Very slight hyperemia of limbal vessels in one quadrant.  
 2 - Mild: Mild hyperemia of limbal vessels in more than one quadrant. 
 3 - Moderate: Marked hyperemia of limbal vessels in any  quadrant. 
 4 - Severe: Marked hyperemia of limbal vessels in all quadrants.  
 Bulbar Injection  
 0 - None: No hyperemia present. Normal appearance of conjunctival vessels.  1 - Trace: Slight hyperemia of conjunctival vessels in one quadrant.  2 - Mild: Mild  hyperemia of conjunctival vessels in more than one quadrant. 
 3 - Moderate: Marked hyperemia of conjunctival vessels in any quadrant.  
 4 - Severe: Marked hyperemia of conjunctival vessels in all quadrants. 
Upper lid tarsal conjunctival abnormalities  
0 - N one: Normal, velvet tarsal conjunctival appearance. No hyperemia or 
enlarged papi[INVESTIGATOR_1257].  
1 - Trace: Slight tarsal conjunctival hyperemia with slight loss of smoothness.  
2 - Mild: Slight tarsal conjunctival hyperemia with slight loss of smoothness. 
Noticeable enlargement of papi[INVESTIGATOR_1257], but <1.0 mm in diameter. 
3 -  Moderate: Definite loss of smoothness with enlarged papi[INVESTIGATOR_1257], but <1.0 mm in diameter with marked tarsal conjunctival hyperemia.  
4 - Severe: Localized or generalized giant papi[INVESTIGATOR_1257], >1.0 mm in diameter and/or severe tarsal conjunctival hyperemia.  

Study 952 - Protocol  
Page B-5 of 72 
Amendment 2, December 9, 2019  Corneal neovascularization 
   0 - None: Normal appearing limbus, including prominent limbal vascular arcades. 
   1 - Trace: Vascularization <1.5 mm of advancement into cornea in one quadrant.    2 - Mild: Vascularization <1.5 mm of advancement into cornea in more than one         
quadrant. 
 3 - Moderate: Vascularization 1.5 mm to <2.5 mm of advancement into cornea in any 
quadrant. 
   4 - Severe: Vascularization >2.5 mm of advancement into cornea in any quadrant. 
Corneal Infiltrates  
   0 - No infiltrates.  
   1 - Single infiltrate; (focal and peripheral), asymptomatic.  
   2 - Single or multiple infiltrate(s); with injection and/or associated symptoms.  
   3 - Single or multiple infiltrate(s); injection with overlying corneal defect(s).  
   4 - Single or multiple infiltrate(s); injection with diffusion of stain into stroma.  
Absent or Present  
New Corneal Scar  
Corneal Striae 
Conjunctivitis  
Other Anterior Segment Abnormalities  External Adnexa Abnormalities 
3.[ADDRESS_292026] lenses at all follow -up visits in the 
Investigator's office.  
Materials needed:    Slit Lamp  
Procedure:    Each lens should be examined on the eye using the slit lamp 
employing a 7X to 15X magnification. 
Classify the deposit and r ecord findings at each visit as follows:  
I. Type of Deposit 
Indicate the type of the most prominent lens surface deposit found using the following classifications:  
• none 
• crystalline deposits  
• crust -like deposits 
• film 
• spots 
 
Study 952 - Protocol  
Page B-6 of 72 
Amendment 2, December 9, 2019  II. Estimated Percentage of Lens Surface Covered By [CONTACT_240399]:  
• none 
• 1  -  25% 
• 26  -  50% 
• 51  -  75% 
• 76  - 100% 
III. Degree of Deposit  
Indicate the degree of the deposit on the lens surface using the following classifications:  
• none 
• light 
• medium  
• heavy 
IV. Wettability  
Grade 0  - 100% of anterior lens surface is wettable 
Grade 1  - Presence of small (<0.1 mm), individual discrete non- wetting areas  
Grade 2  - Presence of single area of non -wetting between 0.1 mm and 0.5 mm in size 
Grade 3  - Presence of several areas of non -wetting between 0.1 mm and 0.5 mm in size 
Grade 4 - Presence of one or more non- wetting areas greater than  0.5 mm in size  
V. Discoloration 
If while on -eye, any discoloration is observed, remove lens and confirm discoloration 
using the following classifications:  [ADDRESS_292027] lenses fit at all visits in the Investigator’s office.  
Materials needed:    Slit Lamp  
Procedure:    Each lens should be examined on the eye using the slit lamp 
employing a 7X to 15X magnification. 
Lens fit will be assessed utilizing the scales below:  
   
Study 952 - Protocol  
Page B-7 of 72 
Amendment 2, December 9, 2019  I. Lens Centration (Enter Rating 0 -3) 
Qualitative  Lens  Centration  
• Compare  lens edge overlap of limbus in all visible sectors.  
• The centration  diagram is pi[INVESTIGATOR_240344]  9:[ADDRESS_292028]. 
• Rate and record  lens centration  on a scale of 0 to 3 based  on the following lens 
diagrams and descri ptors: 
 
0) Equal Overlap 360 degrees 
1) Maximum overlap ≤ 2/3 in any sector  
2) Maximum overlap > 2/3 in any sector 
3) Any Corneal Exposure 
II. Lens Movement  
• As the subject blinks normally, observe lens movement, with particular attention 
to the inferior portion of the lens. 
o All movement depi[INVESTIGATOR_240345]. 
o All movement descriptions apply from the various decent ered positions.  
o Corneal exposure in any sector is an unacceptable fit.  
o If the inferior edge of the contact [CONTACT_240400], gently pull the lower eyelid away.  
• Rate and record lens movement on a scale of -2 to +2 based on the following lens diagrams and  descriptors:  
-2   No observable movement  (perform  Josephson push-up test, see below) 
-1   Minimal; Just  observable movement, lens returns  to origin. 
     0    Optimal/Fre e movement, lens returns  to origin.
  
 +1   Substantial movement; but lens does not immediately return to origin.  
 +2   Excessive movement; lens does not return  to origin, may result  in corneal 
exposur e. 
 
Josephson Push Up Test  
• Use Josephson Push-up test when specified or indicated (- 2 = No observable 
lens movement, see lens movement ratings above). 
o  Apply gentle upward digital pressure to the lower  lid such that the lower  
lid margin  pushes on the inferior  aspect  of the contact  [CONTACT_240401].  
• Determine  if this action  causes the contact  [CONTACT_240402]: 
1 - Lens is mobile 2 - Lens is immobile  
Study 952 - Protocol  
Page C-1 of 72 
Amendment 2, December 9, 2019  APPENDIX C:  CORNEAL INFILTRATES EVALUATION FORM  
Infiltrate Size (Largest):  OD: _____( X.X mm) OS: _____( X.X mm)  
Infiltrate Depth (Deepest):  
OD: _____ OS: _____ 
1. Epi[INVESTIGATOR_018]  
2. Anterior Stroma  
3. Full thickness  
Infiltrate Density:  
OD: _____ OS: _____ 
Grade  Description  
      0 None 
      1 Faint  
      2 Moderate (iris/lens details clear)  
      3 Marked (iris/lens details hazy)  
      4 Intense (iris/lens details obscured)  
Infiltrate Type:  
OD: _____ OS: _____ 
Grades  
0 None 
1 Micropunctate 
2 Macropunctate 
3 Coalesced Macropunctate  
4 Patch  
Ocular Discharge:  
OD: _____ OS: _____ 
1. None 
2. Mucopurulent (green or yellow in color)  
3. Whitish  
4. Watery  
Degree of Pain:  
OD: _____ OS: _____ 
 
Size of any overlying defect: 

Study 952 - Protocol  
Page C-2 of 72 
Amendment 2, December 9, 2019   
OD: _____(X.X mm) OS: _____(X.X mm)  Location: 
Check all that apply  
OD: 
 Central (central 6 mm, 3 mm from corneal center)  
 Nasal  
 Inferior  
 Temporal 
 Superior 
Draw:  
 
OS: 
 Central (central 6 mm, 3 mm from corneal center)  
 Nasal  
 Inferior  
 Temporal 
 Superior 
Draw:   
 

Study 952 - Protocol  
Page D-1 of 72 
Amendment 2, December 9, 2019  APPENDIX D:  CULTURE PROCEDURE  
NOTE: The site must use their standard of care culture kit and ship specimens to 
their local laboratory for testing per the local lab’s required procedures.  Hard copy 
results must be filed in the subject record and entered into the eCRF.  
 
PROCEDURES FOR THE INVESTIGATOR 
A. In the case of corneal ulcer or suspected ocular infection , the cul -de-sac, lower lid 
margin, and the corneal lesion (if applicable)  of the affected eye must be cultured.  
1. Cul-de-sac Culture 
a. The swab from a culture collection kit is moistened in sterile, physiological 
saline solution, with no preservatives. 
b. The ocular specimen is obtained by [CONTACT_240403]. The moistened swab should be drawn across the cul -
de-sac while rotating the swab [ADDRESS_292029] the swab in the transport tube  media  according to manufacturer's 
directions.  
d.  Repeat steps a through c using a separate swab and a separate tube of transport media for the other eye if both eyes require culturing. 
2. Eyelid Culture  
a. The swab from a culture collection kit is moistened in  sterile, physiological 
saline solution, with no preservatives. 
b. The specimen is obtained from the margin of the lower lid by [CONTACT_240404]. 
c. Place the swab in the transport tube media according to manufacturer's 
directio ns. 
d. Repeat steps a through c using a separate swab and a separate tube of transport media for the other eye if both eyes require culturing. 
3. Corneal Culture  
a. The swab from a culture collection kit is moistened in sterile, physiological saline soluti on, with no preservatives. 
b. The specimen is obtained from the corneal lesion by [CONTACT_240405] [ADDRESS_292030] the swab in the transport tube media according to manufacturer's 
directions.  
d. Repeat steps a through c using a separate swab and a separate tube of transport media for the other eye if both eyes require culturing. 
 
Study 952 - Protocol  
Page D-2 of 72 
Amendment 2, December 9, 2019  B.  Labeling and Transportation of Cultures to the Clinical Laboratory: 
 
1. Complete the report form supplied by [CONTACT_240406]. Affix labels supplied in the culture collection kit to the 
ocular specimens as well as to the container used to transport the contact [CONTACT_240407] (which contains the contact [CONTACT_13293][es] and contact [CONTACT_240408]) if available.  
2. The specimens, contact [CONTACT_13293](es), lens case(s), lens case solution(s) and report form are then sent to the central laboratory under refrigerated conditions using the supplies provided by [CONTACT_2237].
Study 952 - Protocol  
Page E-1 of 72 
Amendment 2, December 9, 2019  APPENDIX E:  SUBJECT INSTRUCTIONS  – SOFT CONTACT [CONTACT_240409] a study evaluating the safety and effectiveness of an 
Investigational Lubricating and Rewetting Drop compared to a marketed rewetting drop. Please keep all appointments and follow these instructions thoroughly . If you have any 
questions or problems, consult your study doctor.  
 NOTE:  It is important to wear your study lenses to each of your follow- up visits and 
place [ADDRESS_292031] INFORMATION:  
For this study, you will be using the following products: 
• Study Rewetting Drops  
o You will receive 1 carton  that will contain either 6  multi-dose bottles or 56 
pouches of 5 single- use dispenser s. 
• Study Contact [CONTACT_32993]  
o You will be provided with [ADDRESS_292032] lenses at the 
start of the study. One pair will be used as back-up, only if needed. 
• Other Study Supplies.   The following supplies will be provided to you as 
needed: 
o One [ADDRESS_292033] Instructions.   A copy of this sheet to be included. 
• Carton/Bottle/Single -Use Dispenser Return Materials.
  Opaque, drawstring 
bag to place all study materials  into, including Study Kit (carton) with unused 
study rewetting drops, zippered bag for returning  partially full, and empty multi-
dose drop b ottles  or opened single- use dispensers along with all worn and unworn 
lenses.  
  
  
Study [ADDRESS_292034] INSTRUCTIONS (continued , page 2 of 4) 
 
IMPORTANT SUBJECT INSTRUCTIONS:  
This is a “masked” clinical study in which the Investigators and Coordinators 
cannot see the Study Drops that are dispensed to you.  There will be a special study 
employee – the “unmasked designee” – at the site who will dispense all study 
materials to you  in a white drawstring bag and who will handle any questions you 
have related to the study materials.   
 
It is very important that you keep your study drops in the opaque white bag when 
coming to the study visits.  
 
 
GENERAL INFORMATION:  
• Do NOT use any products other than those listed above or dispensed to you by 
[CONTACT_240410]. 
• Do NOT use any other care products other than those listed above. 
• Do not use any topi[INVESTIGATOR_213726] (eye drops) during this study. 
• Do NOT discuss  or show the dispensed study products or these Subject 
Instructions to the study doctor  or site staff  other than the “unmasked designee”  
during the study. 
• Save ALL study materials (drops and lenses) during the course of the study in the 
subject opaque draw string take -home bag.  Bring all opened and unopened study 
materials (drops and lenses) to the 1-month follow- up/exit visit.  Place the  multi-
dose bottles or single-use dispensers, lens cases, and worn and unworn lenses into 
the white  drawstring bag provided.  
• Always wash and rinse your hands before you handle your lenses. 
• Always handle the same lens (right or left) first, to avoid mix -ups. 
• Always keep the products tightly closed when not in use. 
• Lenses must be thoroughly cleaned, rinsed, and soaked using Biotru e multi -
purpose solution each time they are removed to achieve disinfection.  See the 
Package Insert printed on the inside of the Biotrue multipurpose solution carton for important safety information.  
• Rinse each case well with the Biotrue  multi- purpose solution before and after 
each use. 
PRECAUTIONS:  
• Lens care procedures recommended by [CONTACT_240411].  
• Failure to follow these procedures may result in the development of serious eye infections. 
• Discard the Biotrue  multi -purpose solution from the lens case after each use.  
• Store Study Drops and Biotrue multi -purpose solution at room temperature.  
SUBJECT INSTRUCTIONS (continued, page 3 of 4)  
Study 952 - Protocol  
Page E-3 of 72 
Amendment 2, December 9, 2019   
• Use Biotrue  multi -purpose solutio n before the expi[INVESTIGATOR_240346]. 
• Do not use any eye medication in conjunction with the Study Drops and Biotrue 
multi -purpose solution unless under medical supervision.  
• Do not touch the tip of the Study Drops  or Biotrue multi -purpose solution to 
any surface or to your eye since this may contaminate the study solutions.  
• Keep the Study Drops and Biotrue multi -purpose solution cap closed when not 
in use to avoid contamination or evaporation. 
• Do not use Biotrue  multi -purpose s olution  with a heat disinfection method. 
• Keep Study Drops and Biotrue multi -purpose solution out of reach of children. 
• Consult with your study doctor if you have any allergies that may affect your 
ability to use the Study Drops or Biotrue multi -purpose solution. 
IMPORTANT:  
• If irritation or excessive tearing occurs, persists or increases, or if vision is impaired, discontinue use and promptly consult your study doctor. 
REWETTING DROP [LOCATION_003]GE:  
Place study rewetting drops in each eye at least 4 times every day that lenses are worn 
during the one month you are in this study:  
• During wear, place 1 to 2 study rewetting dro ps in the eye and blink.  To avoid 
contamination, do not touch tip of container to any surface.  
• As required by [CONTACT_15365], always place  drops in the eye 30 to 60 minutes before 
removing the lenses each day .  
• If you have multi-dose bottles, r eplace the cap  on the bottle  after each treatment . 
Begin with “Bottle 1”. When “Bottle 1” is empty place in zippered bag to return at exit 
visit. Open “Bottle 2” and continue to use until empty and place in zippered bag to return at exit visit. Continue to open the next sequential bottle when the last bottle opened becomes empty.  Always keep products tightly closed when not in use.  All bottles, used and unused will need to be returned at your exit visit. 
• If you have single-use dispenser, to open, completely twist off tab and use one dispenser to treat both lenses at each treatment interval. Do not use the dispenser again after treatment even though there may be remaining drops in the dispenser.  Place the used dispenser in the zipper bag to return at end of study.  All single- use dispensers, 
used and unused will need to be returned at your exit visit. 
 
Remember: It’s important to wear your study lenses to each of your follow -up visits 
and pl ace [ADDRESS_292035] INSTRUCTIONS (Page 4 of 4) 
 
LENS CLEANING INSTRUCTIONS :  
See the Package Insert printed on the inside of the Biotrue multipurpose solution 
carton for important safety information . 
When used as directed, Biotrue multi -purpose solution: Conditions, Cleans, R emoves 
Protein , Disinfects , Rinses and S tores.  
Directions: To condition, clean, remove protein and disinfect lenses, complete these simple steps. This daily regimen is recommended by [CONTACT_59268] + Lomb for a healthy and comfortable contact [CONTACT_240412]:  
STEP 1:  Place at least 3 drops of Biotrue multi- purpose solution on each side of lens 
surface and gently rub for 20 seconds.  STEP 2:  Thoroughly rinse each side of the lens for 5 seconds with Biotrue multi-
purpose solution.  STEP 3:  Place cleaned contact [CONTACT_240413] -
purpose solution. Soak at least 4 hours. Remember to always use fresh solution – discard 
solution from lens case after each use.  
Your lenses are now ready to wear. If any debris remains on contact [CONTACT_13276], rinse with 
Biotrue multi -purpose so lution  prior to insertion. 
 Always follow your study doctor’s instructions.  
If not wearing contact [CONTACT_240414], store them in a closed lens case. Do not store 
your lenses in simple saline in place of Biotrue multi- purpose solution.  Saline solution  
and study rewetting drops will not disinfect.  
CARE OF THE STUDY LENS STORAGE CASE:  
Clean, rinse and air -dry your lens case each time you remove your lenses. In order to 
permit excess solution to drain, you can flip over your lens case while air drying. 
• For visits to the office  other than the 1-month follow-up/ exit visit, you do not need to 
bring the lens case to the office.    
• If there is a reason to bring any material provided to you for this study to the office, 
PLACE THEM IN THE WHITE OPAQUE BAG FOR TRANSFER TO THE OFFICE.  
   
Study 952 - Protocol  
Page F-1 of 72 
Amendment 2, December 9, 2019  APPENDIX F:  SUBJECT INSTRUCTIONS  – RIGID CONTACT [CONTACT_240415] a study evaluating the safety and effectiveness of an Investigational 
Lubricating and Rewetting Drop compared to a marketed rewetting drop. Please keep all appointments and follow these instructions thoroughly . If you have any questions or problems, 
consult your study doctor.   NOTE:  It is important to w ear your study lenses to each of your follow- up visits and place [ADDRESS_292036] INFORMATION:  
For this study, you will be using the following products: 
• Study Rewetting Drops  
o You will receive 1 carton  that will contain either 6  multi-dose bottles or 56 pouches of 
5 single- use dispenser s. 
• Study Contact [CONTACT_32993]  
o You will be provided with [ADDRESS_292037] lenses at the start of the study. One pair will be used as back -up, only if needed.  
• Other Study Supplies.   The following supplies will be provided to you as needed: 
o Three  3.[ADDRESS_292038] Instructions.   A copy of this sheet to be included. 
 
• Carton/Bottle/Single -Use Dispenser Return Materials.
  Opaque, drawstring bag to 
place all study materials  into, including Study Kit (carton) with unused study rewetting 
drops, zippered bag that contains partially full, and empty study rewetting  drop bottles  or 
opened single- use dispensers along with all worn and unworn lenses. 
  
Study [ADDRESS_292039] INSTRUCTIONS (continued , page 2 of 4)  
IMPORTANT SUBJECT INSTRUCTIONS:  
This is a “masked” clinical study in which the Investigators and Coordinators cannot see 
the Study Drops that are dispensed to you.  There will be a special study employee – the 
“unmasked designee” – at the site who will dispense all study materials to you  in a white 
drawstring bag and who will handle any questions you have related to the study materials.   
 
It is very important that you keep your study drops in the white bag when coming to the study 
visits.     
GENERAL INFORMATION:  
• Do NOT use any products other than those listed above or dispensed to you by [CONTACT_240416]. 
• Do NOT use any other care products other than those listed above. 
• Do not use any topi[INVESTIGATOR_213726] (eye drops) during this study. 
• Do NOT discuss or show the dispensed study products or these Subject Instructions to the Study doctor or site staff other than the “unmasked designee” during the study.  
• Save ALL study materials (drops and lenses) during the course of the study in the subje ct 
opaque drawstring take-home bag.  Bring all opened and unopened study materials (drops and lenses) to the 1-month follow- up/exit visit.  Place the multi -dose bottles  or single -use 
dispensers, lens cases, and unworn lenses into the opaque drawstring bag provided.  
• Always wash and rinse your hands before you handle your lenses. 
• Always handle the same lens (right or left) first, to avoid mix -ups. 
• Always keep the products tightly closed when not in use. 
• Lenses must be thoroughly soaked, cleaned, and rinsed using [LOCATION_011] SIMPLUS  Multi-
Action  Solution  each time they are removed to achieve disinfection.   See the Package 
Insert printed on the inside of the [LOCATION_011] SIMPLUS  Multi-Action  Solution carton 
for important safety information . 
• Before first and after each use, always empty and rinse the lens case with the  [LOCATION_011] 
SIMPLUS Multi -Action Solution  and allow to air dry.  
PRECAUTIONS:   
• Lens care procedures recommended by [CONTACT_240411].  
• Failure to follow these proced ures may result in the development of serious eye 
infections. 
• Discard the [LOCATION_011] SIMPLUS  Multi-Action  Solution  from the lens case after each use.  
• Store Study Drops and [LOCATION_011] SIMPLUS M ulti-Action  Solution  at room temperature.  
• Use [LOCATION_011] SIMPLUS  Multi-Actio n Solution  before the expi[INVESTIGATOR_240346]. 
• Do not use any eye medication in conjunction with the Study Drops and [LOCATION_011] SIMPLUS M ulti-Action  Solution  unless under medical supervision. 
Study [ADDRESS_292040] INSTRUCTIONS (continued, page 3 of 4)  
• Do not touch the tip of the Study Drops  or [LOCATION_011] SIMPLUS M ulti-Action  Solution  to 
any surface or to your eye since this may contaminate the study solutions.  
• Keep the Study Drops and [LOCATION_011] SIMPLUS M ulti-Action  Solution  cap closed  when 
not in use to avoid contamination or evaporation. 
• Keep Study Drops and [LOCATION_011] SIMPLUS M ulti-Action  Solution  out of reach of 
children.  
• Consult with your study doctor if you have any allergies that may affect your ability to 
use the Study Drops or  Bost on SIMPLUS M ulti-Action  Solution . 
IMPORTANT:   
• If irritation or excessive tearing occurs, persists or increases, or if vision is impaired, discontinue use and promptly consult your study doctor. 
REWETTING DROP [LOCATION_003]GE:  
Place study rewetting drops in each eye at least 4 times every day that lenses are worn during the 
one month you are in this study:  
• During wear, place 1 to 2 study rewetting drops in the eye and blink.  To avoid contamination, 
do not touch tip of container to any sur face.   
• As required by [CONTACT_15365], always place  drops in the eye 30 to 60 minutes before rem oving the 
lenses each day .  
• If you have multi-dose bottles, replace the cap on the bottle. Always keep products tightly 
closed when not in use.  
• If you have single-use dispenser, to open, completely twist off tab and use one dispenser at each treatment interval to treat both lenses.  Do not use the dispenser again after treatment even though there may be remaining drops in the dispenser.  Place the used dispenser in the zippered bag to return at end of study.  All single -use dispensers, used and unused will need to 
be returned at your exit visit.  
Remember: It’s important to wear your study lenses to each of your follow -up visits and place 
[ADDRESS_292041] INSTRUCTIONS (Page 4 of 4)  
LENS CLEANING INSTRUCTIONS :  
See the Package Insert printed on the inside of the [LOCATION_011] SIMPLUS  Multi-Action  Solution 
carton for important safety information . 
 
To ensure proper disinfecting, all steps listed below must be followed :  
1. Wash your hands with mild soap. (Caution - pump soaps may contain oil- based 
suspension agents.)  
2. Place lenses in empty lens case and fill with fresh [LOCATION_011] SIMPLUS Multi -Action 
Solution . Soak lenses for at least 4  hours (or overnight) before wearing.  
3. Wash hands with mild soap before cleaning (rubbing) lenses.  After soaking, remove 
lenses from lens case and rub both sides of the lenses carefully with [ADDRESS_292042] solution from lens case after each use.   
 Always follow your study doctor’s instructions. 
If not wearing contact [CONTACT_240414], store them in a closed lens case. Do not store your 
lenses in simple saline in place of [LOCATION_011] SIMPLUS  Multi-Action  Solution . Never use water, 
saline solution or study rewetting drops to disinfect your lenses.  These solutions will not disinfect your lenses.  
 You should not expose or store your lenses in or rinse your lens case with any water, such 
as tap, distilled, or with any non- sterile solution.  
CARE OF THE STUDY LENS STORAGE CASE:   
Clean contact [CONTACT_240417] -Action 
Solution . Never use water. Cleaning should be followed by [CONTACT_240418] -Action Solution (never use water) and wipi[INVESTIGATOR_240347] a fresh,  
clean tissue is recommended.  Air-drying or recappi[INVESTIGATOR_240348]. If air drying, be sure that no residual solution 
remains in the case before allowing it to air dry.  
• For visits to the office  other than the 1-month follow up/exit visit, you do not need to bring 
the lens case to the office.    
• If there is a reason to bring the lens case to the office, PLACE THE LENS CASE IN THE WHITE OPAQUE BAG FOR TRANSFER TO THE OFFICE.  
 NOTE:  For care of lens storage case please follow the above instructions for care of your lens 
storage case instead of the instructions printed on the [LOCATION_011] SIMPLUS Multi -Action Solution 
bottle and carton.  
 
 